STI & HIV 2019 SUPPORTERS

STI & HIV 2019 would like to thank the following companies for their generous support:

SPONSORS

PLATINUM LEVEL

GOLD LEVEL

SILVER LEVEL

BRONZE LEVEL

OTHER SUPPORTERS

BD MAX™ Vaginal Panel

One clinician- or patient-collected vaginal swab provides results for the three most common causes of vaginitis – bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis (TV).1

In addition, BD MAX Vaginal Panel utilizes the CDC-recommended diagnostic technology for *T. vaginalis* detection2 and provides three results for microorganisms responsible for yeast infections:

- **Candida group**, including *C. albicans*, *C. parapsilosis*, *C. tropicalis*, and *C. dubliniensis*
- Differentiates fungal species – *C. glabrata* and *C. kruisi* – associated with antimicrobial resistance3.

The BD MAX™ Women’s Health and STI portfolio is focused on providing accurate, reliable results that enable clinicians and labs to elevate patient care.

- BD MAX™ Vaginal Panel
- BD MAX™ CT/GC/TV
- BD MAX™ GBS

Reference

1. BD MAX Vaginal Panel Package Insert

BD, the BD Logo and the BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. April 2019.
Dear Friends and Colleagues,

On behalf of the Organizing Committee, we are delighted you have decided to attend the STI & HIV 2019 World Congress to be held July 14 – 17, 2019, at the Vancouver Convention Centre East Building, in Vancouver, British Columbia, Canada.

This Congress is a joint meeting of the International Society for Sexually Transmitted Diseases Research (ISSTDR) and the International Union Against Sexually Transmitted Infections (IUSTI). This biennial meeting is the world’s largest international meeting on sexually transmitted infections, drawing delegates from around the globe.

Under the theme of ‘The Evolving Landscape of STI and HIV Elimination’, this meeting will provide an excellent opportunity for the world’s most prominent researchers and health professionals to come together in the shared goal of improving global public health in the field of sexually transmitted infections, including HIV. The meeting will provide Congress attendees the opportunity to network with experts, present their research findings to an international audience, hear the latest scientific developments from world leaders in the STI/HIV field, and contribute to discussions that will shape future health policies and patient care around the world.

The STI & HIV 2019 World Congress is taking place in one of the most stunning cities in the world. Vancouver is a safe, modern, multicultural city with a vibrant local arts and culture scene and abundant opportunities for outdoor adventures amongst a setting of incomparable natural beauty.

We welcome you to Vancouver and look forward to providing you with an exceptional scientific and cultural experience!

Warm regards,

Caroline Cameron, Chair
International Society for Sexually Transmitted Diseases Research, President
University of Victoria, Canada

Charlotte Gaydos, Co-Chair
International Union Against Sexually Transmitted Infections, President
Johns Hopkins University, USA

A Message from the Mayor

On behalf of my colleagues on Vancouver City Council and the citizens of Vancouver I want to extend my warmest greetings to the delegates of the International Society for Sexually Transmitted Diseases Research (ISSTDR) and the International Union Against Sexually Transmitted Infections (IUSTI) who are co-hosting the STI & HIV 2019 World Congress.

The opportunity to share research and scientific developments is crucial to developing policies and platforms that enhance the well-being of all citizens. With the goal of improving global public health in the field of sexually transmitted infections including HIV/AIDS, ISSTDR and IUSTI help shape discussions around future health policies and patient care around the world.

We are proud to host the STI & HIV 2019 World Congress in Vancouver and I hope that in addition to attending the conference you are able to experience the many cultural and recreational activities the City has to offer. I know everyone involved in organizing the conference will ensure your time with us is special.

Best wishes on a successful and productive conference.

Mayor Kennedy Stewart
Scientific Committee

Co-Chairpersons

David Lewis
Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia; Westmead Clinical School, University of Sydney, Sydney, Australia; Division of Medical Virology, University of Cape Town, Cape Town, South Africa

James Blanchard
Departments of Community Health Sciences and Medical Microbiology, Centre for Global Public Health, Canada Research Chair in Epidemiology and Global Public Health, Faculty of Medicine University of Manitoba

Basic & Translational Science Track Team

Chairperson:
Sheila Lukehart
University of Washington, USA

Track Members:
Jo-Anne Dillon
Canada
Laura Sycuro
Canada
Magnus Unemo
Sweden
David Whiley
Australia
Will Geisler
USA
Nick Thomson
UK
Anna Wald
USA

Clinical Science Track Team

Chairperson:
Matthew Golden
University of Washington (UW) School of Medicine, Seattle & King County HIV/STD Program, UW Public Health Capacity Building Center, USA

Track Members:
Catriona Bradshaw
Australia
Julie Dombrowski
USA
Daniel Richardson
Australia
Ping Yu Zhou
China

Epidemiology & Monitoring Track Team

Chairperson:
Gwenda Hughes
National Infection Service at Public Health England, Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP), UK

Track Members:
Michel Alary
Canada
Viviane Bremer
Germany
Sinead Delaney-Moretliwe
South Africa
Jane Hocking
Australia

Policy & Community Engagement Track Team

Chairperson:
Helen Ward
Imperial College London, UK

Track Members:
Patricia Garcia
Peru
Maryam Shahmanesh
UK
Morten Skovdal
Denmark

Behavioural & Social Sciences Track Team

Chairperson:
Jacky Jennings
Johns Hopkins School of Medicine, Bloomberg School of Public Health, Center for Child and Community Health Research, USA

Track Members:
Valeria Stuardo Avila
Chile
Kit Fairley
Australia
Joe Tucker
USA
Sarah Bernays
Australia
Robert Lorway
Canada

Co-Chairpersons

Chairperson:
Basic & Translational Science Track Team
David Lewis
Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia; Westmead Clinical School, University of Sydney, Sydney, Australia; Division of Medical Virology, University of Cape Town, Cape Town, South Africa

James Blanchard
Departments of Community Health Sciences and Medical Microbiology, Centre for Global Public Health, Canada Research Chair in Epidemiology and Global Public Health, Faculty of Medicine University of Manitoba

Track Members:
Jo-Anne Dillon
Canada
Laura Sycuro
Canada
Magnus Unemo
Sweden
David Whiley
Australia
Will Geisler
USA
Nick Thomson
UK
Anna Wald
USA

Clinical Science Track Team

Chairperson:
Matthew Golden
University of Washington (UW) School of Medicine, Seattle & King County HIV/STD Program, UW Public Health Capacity Building Center, USA

Track Members:
Catriona Bradshaw
Australia
Julie Dombrowski
USA
Daniel Richardson
Australia
Ping Yu Zhou
China

Epidemiology & Monitoring Track Team

Chairperson:
Gwenda Hughes
National Infection Service at Public Health England, Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP), UK

Track Members:
Michel Alary
Canada
Viviane Bremer
Germany
Sinead Delaney-Moretliwe
South Africa
Jane Hocking
Australia

Policy & Community Engagement Track Team

Chairperson:
Helen Ward
Imperial College London, UK

Track Members:
Patricia Garcia
Peru
Maryam Shahmanesh
UK
Morten Skovdal
Denmark

Behavioural & Social Sciences Track Team

Chairperson:
Jacky Jennings
Johns Hopkins School of Medicine, Bloomberg School of Public Health, Center for Child and Community Health Research, USA

Track Members:
Valeria Stuardo Avila
Chile
Kit Fairley
Australia
Joe Tucker
USA
Sarah Bernays
Australia
Robert Lorway
Canada
**Program & Implementation Science Track Team**

**Chairperson:**
Sevgi Aral  
US Centers for Disease Control, University of Washington, Emory University, USA, University of Manitoba, Canada  
Parinita Bhattacharjee  
Kenya/Canada  
Harrell Chesson  
USA  
James Hargreaves  
UK  
Sharmistha Mishra  
Canada  
Ian Spicknall  
USA  
Anneli Uusküla  
Estonia  

**Track Members:**

**Local Organizing Committee**

**Chair:**
Caroline Cameron  
University of Victoria, Canada  
Jessica Chenery  
Penelakut, Chee Mamuk, Clinical Prevention Services, BC Centre for Disease Control  
Jeanne Marrazzo  
University of Alabama, USA  
Mark Gilbert  
British Columbia Centre for Disease Control, Canada  
Sara Chown  
YouthCO HIV & Hep C Society  
Jennifer Coward  
Indigenous Wellness Team, First Nations Health Authority  
Andrea Derban  
Indigenous Wellness Team, First Nations Health Authority  
Troy Grennan  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Mark Lachowsky  
University of Victoria, Canada  
Nathan Lachowsky  
University of Victoria & Community Based Research Centre  
Matthew Louie  
Indigenous Wellness Team, First Nations Health Authority  
Lindsey Frehlick  
University of Victoria, Canada  
Sarah Chown  
YouthCO HIV & Hep C Society  
Ameeta Singh  
University of Alberta  
Larissa Wahpoosayan  
Yuusnewas Program, YouthCO HIV & Hep C Society  
Rupert Kaul  
University of Toronto, Canada  
Dennis Fortenberry  
Indiana University, USA  
Jeanne Marrazzo  
University of Alabama, USA  
Matthew Louie  
Indigenous Wellness Team, First Nations Health Authority  
Lisa Manhart  
University of Washington, USA  
Barbara Van Der Pol  
University of Alabama, USA  
Gina Ogilvie  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Gina Ogilvie  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Michael Rekart  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Nathan Lachowsky  
University of Victoria & Community Based Research Centre  
Mel Krajden  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Mark Gilbert  
British Columbia Centre for Disease Control, Canada  
Deborah Money  
University of British Columbia, Canada  
Mark Tyndall  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Jane Hocking  
University of Melbourne, Australia  
Gina Ogilvie  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Ameeta Singh  
University of Alberta, Canada  
Nathan Lachowsky  
University of Victoria & Community Based Research Centre  
Mel Krajden  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Mark Gilbert  
British Columbia Centre for Disease Control, Canada  
Deborah Money  
University of British Columbia, Canada  
Mark Tyndall  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Nathan Lachowsky  
University of Victoria & Community Based Research Centre  
Mel Krajden  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Mark Gilbert  
British Columbia Centre for Disease Control, Canada  
Deborah Money  
University of British Columbia, Canada  
Mark Tyndall  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Larissa Wahpoosayan  
Yuusnewas Program, YouthCO HIV & Hep C Society  
Nathan Lachowsky  
University of Victoria & Community Based Research Centre  
Mel Krajden  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Mark Gilbert  
British Columbia Centre for Disease Control, Canada  
Deborah Money  
University of British Columbia, Canada  
Mark Tyndall  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Larissa Wahpoosayan  
Yuusnewas Program, YouthCO HIV & Hep C Society  
Mel Krajden  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Mark Gilbert  
British Columbia Centre for Disease Control, Canada  
Deborah Money  
University of British Columbia, Canada  
Mark Tyndall  
University of British Columbia, British Columbia Centre for Disease Control, Canada  
Larissa Wahpoosayan  
Yuusnewas Program, YouthCO HIV & Hep C Society

**nécaʔmat ct Indigenous Sexual Health Committee**

The purpose of this committee is to raise the prominence of Indigenous sexual health within the conference and to work with the Local Organizing Committee to establish relations in a good way with the local Coast Salish peoples on whose traditional, ancestral and unceded territories the conference is held, specifically the Sḵwx̱wú7mesh (Squamish), Sel̓íl̓witulh (Tsleil-Waututh), and x̱məθkwəy̓ əm (Musqueam) Nations.

We are grateful to the Elders of the VCH Aboriginal Health Elder Advisory Council for guiding us in doing this work, including Elder Roberta Price, Elder Doris Fox, Elder Iris Newman, Elder Iggy George, Elder Dee George, Elder Marr Dorvault, Elder Gilda Morgan, Elder Lillian Daniels, and Elder Jean Wasegijig.

The word nécaʔmat ct embodies the concept of “We are One” in the hən̓q̣̑əmin̓ə̓m̓ (Musqueam) language.

**Committee Members**

Jessica Chenery  
Penelakut, Chee Mamuk, Clinical Prevention Services, BC Centre for Disease Control  
Sarah Chown  
YouthCO HIV & Hep C Society  
Jennifer Coward  
Indigenous Wellness Team, First Nations Health Authority  
Andrea Derban  
Indigenous Wellness Team, First Nations Health Authority  
Jeanne Marrazzo  
University of Alabama, USA  
Nathan Lachowsky  
University of Victoria & Community Based Research Centre  
Matthew Louie  
Indigenous Wellness Team, First Nations Health Authority  
Barbara Van Der Pol  
University of Alabama, USA  
Larissa Wahpoosayan  
Yuusnewas Program, YouthCO HIV & Hep C Society  
Ameeta Singh  
University of Alberta  
Larissa Wahpoosayan  
Yuusnewas Program, YouthCO HIV & Hep C Society  
Mark Tyndall  
University of British Columbia, British Columbia Centre for Disease Control, Canada
The International Society for Sexually Transmitted Diseases Research (ISSTDR) exists to promote research on sexually transmitted diseases and facilitate the timely exchange of information among research investigators. To these ends, ISSTDR sponsors a biennial, interdisciplinary scientific meeting. The ISSTDR meetings have been the premier scientific conferences that address the entire breadth of research on STDs, including HIV, and encompasses microbiology, virology, immunobiology, pathogenesis, and other basic sciences; clinical sciences, social and behavioral sciences, epidemiology, and prevention; and research in health services, public health, and prevention policy.

ISSTDR was founded in 1977 and is governed by an international Board of Directors who currently represent 6 countries. The ISSTDR Conference Support Foundation provides support in respect of the conferences of the ISSTDR.

The International Union against Sexually Transmitted Infections (IUSTI) was founded in 1923 and it is organized on both a global and regional basis. It is the oldest international organization with the objective of fostering international cooperation in the control of sexually transmitted infections including HIV/AIDS. IUSTI is concerned with the medical, scientific, social and epidemiological aspects of sexually transmitted infections and their control.

IUSTI is on the Roster of the United Nations Economic and Social Council. It is an Official Non-Government Organization in Consultative Status with the World Health Organization. IUSTI organizes frequent international and regional conferences on sexually transmitted infections and, in collaboration with the International Journal for STD and AIDS, publishes expert clinical guidelines for their management.
### ISSTDR BOARD LISTING

<table>
<thead>
<tr>
<th>NAME</th>
<th>COUNTRY</th>
<th>ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caroline Cameron</td>
<td>Canada</td>
<td>President</td>
</tr>
<tr>
<td>Henry de Vries</td>
<td>Netherlands</td>
<td>President-Elect</td>
</tr>
<tr>
<td>Jeanne Marrazzo</td>
<td>USA</td>
<td>Immediate Past President and ISSTDR Foundation President</td>
</tr>
<tr>
<td>Basil Donovan</td>
<td>Australia</td>
<td>Past President and Chair of the 21st Meeting, 2015</td>
</tr>
<tr>
<td>Barbara Van Der Pol</td>
<td>USA</td>
<td>Secretary General</td>
</tr>
<tr>
<td>Christopher Fairley</td>
<td>Australia</td>
<td>Member</td>
</tr>
<tr>
<td>Edward Hook III</td>
<td>USA</td>
<td>Member</td>
</tr>
<tr>
<td>Nicola Low</td>
<td>Switzerland</td>
<td>Member</td>
</tr>
<tr>
<td>Helen Ward</td>
<td>UK</td>
<td>Member</td>
</tr>
<tr>
<td>Jeff Klausner</td>
<td>USA</td>
<td>Member</td>
</tr>
<tr>
<td>Jane Hocking</td>
<td>Australia</td>
<td>Member</td>
</tr>
<tr>
<td>Charlotte Gaydos</td>
<td>USA</td>
<td>IUSTI World President, Observer</td>
</tr>
<tr>
<td>Gail Bolan</td>
<td>USA</td>
<td>CDC Observer</td>
</tr>
</tbody>
</table>

### IUSTI EXECUTIVE COMMITTEE LISTING

<table>
<thead>
<tr>
<th>NAME</th>
<th>COUNTRY</th>
<th>ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charlotte A Gaydos</td>
<td>USA</td>
<td>President</td>
</tr>
<tr>
<td>Janet Wilson</td>
<td>UK</td>
<td>President-Elect</td>
</tr>
<tr>
<td>David Lewis</td>
<td>Australia</td>
<td>Immediate Past President</td>
</tr>
<tr>
<td>Elizabeth Foley</td>
<td>UK</td>
<td>Secretary General</td>
</tr>
<tr>
<td>Jonathan Ross</td>
<td>UK</td>
<td>Treasurer</td>
</tr>
<tr>
<td>Christopher Fairley</td>
<td>Australia</td>
<td>Assistant Secretary General &amp; Webmaster</td>
</tr>
<tr>
<td>Bradley Stoner</td>
<td>USA</td>
<td>Membership Secretary</td>
</tr>
<tr>
<td>Francis Ndowa</td>
<td>Zimbabwe</td>
<td>Regional Director, Africa-MENA</td>
</tr>
<tr>
<td>Somesh Gupta</td>
<td>India</td>
<td>Regional Director, Asia Pacific</td>
</tr>
<tr>
<td>Airi Pöder</td>
<td>Estonia</td>
<td>Regional Director, Europe</td>
</tr>
<tr>
<td>Adele Schwartz Benzaken</td>
<td>Brazil</td>
<td>Regional Director, Latin America and the Caribbean</td>
</tr>
<tr>
<td>Cornelis Rietmeijer</td>
<td>USA</td>
<td>Regional Director, North America</td>
</tr>
<tr>
<td>Amina Hansali</td>
<td>Morocco</td>
<td>Regional Chair, Africa-MENA</td>
</tr>
<tr>
<td>Kaushal Verma</td>
<td>India</td>
<td>Regional Chair, Asia Pacific</td>
</tr>
<tr>
<td>Claudia Heller-Vitouch</td>
<td>Austria</td>
<td>Regional Chair, Europe</td>
</tr>
<tr>
<td>Angelica Espinosa Miranda</td>
<td>Brazil</td>
<td>Regional Chair, Latin America and the Caribbean</td>
</tr>
<tr>
<td>Barbara Van Der Pol</td>
<td>USA</td>
<td>Regional Chair, North America</td>
</tr>
<tr>
<td>Sarah Lowe</td>
<td>Zimbabwe</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Ranmini Kularatne</td>
<td>South Africa</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Keith Radcliffe</td>
<td>UK</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Edward Hook III</td>
<td>USA</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Dennis Fortenberry</td>
<td>USA</td>
<td>Elected Member</td>
</tr>
</tbody>
</table>
**IUSTI Executive Committee Listing**

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunil Sethi</td>
<td>India</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Maria Eugenia Escobar</td>
<td>Argentina</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Patricia Galarza</td>
<td>Argentina</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Gloria Aguilar</td>
<td>Paraguay</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Laith Abu-Raddad</td>
<td>Qatar</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Ryoichi Hamasuna</td>
<td>Japan</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Suzanne Garland</td>
<td>Australia</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Marco Cusini</td>
<td>Italy</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Mihael Skerlev</td>
<td>Croatia</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Jo-Anne Dillon</td>
<td>Canada</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Nathalie Broutet</td>
<td>Switzerland</td>
<td>WHO Liaison Officer</td>
</tr>
<tr>
<td>Caroline Cameron</td>
<td>Canada</td>
<td>ISSTDR President, Observer</td>
</tr>
<tr>
<td>Raj Patel</td>
<td>UK</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Chavalit Mangkalaviraj</td>
<td>Thailand</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Patricia Garcia</td>
<td>Peru</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Lew Drusin</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Julius Schachter</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Thomas Quinn</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Sevgi Aral</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Angelika Stary</td>
<td>Austria</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Hunter Handsfield</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Mikhail Gomberg</td>
<td>Russia</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>King Holmes</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
</tbody>
</table>

**Keynote, Plenary & Debate Speakers**

**Keynote Speakers**

Dr. Rino Rappuoli

*GSK Vaccines, Italy*

Dr. Rino Rappuoli is Chief Scientist and Head of External R&D at GSK Vaccines, based in Siena, Italy and Professor at Imperial College, London, UK. Prior positions include Head of Vaccine R&D at Novartis, CSO of Chiron Corporation, and Head of R&D at Sclavo. He obtained his PhD in Biological Sciences at the University of Siena, Italy, and has been a visiting scientist at both Rockefeller University and Harvard Medical School in the United States.

He is elected member of US National Academy of Sciences (NAS), American Academy of Arts and Sciences (AAAS), the European Molecular Biology Organization (EMBO), and the Royal Society of London. Dr. Rappuoli has received numerous awards including the Gold Medal of the Italian President, the Albert B Sabin Gold Medal, the Canada Gairdner International Award and the European Inventor Award for Lifetime Achievement. He was recently nominated as the third most influential person worldwide in the field of vaccines (Terrapin). He has published more than 650 works in peer-reviewed journals.

Dr. Rappuoli has developed and implemented a number of novel scientific concepts critical for vaccine development in the areas of genetic detoxification, cellular microbiology, reverse vaccinology and the pangenome. With others, he has developed several licensed vaccines and related adjuvants/carriers, including the acellular pertussis vaccine, which contains a non-toxic mutant of pertussis toxin; the first conjugate vaccine against meningococcus C; MF59, the first vaccine adjuvant after aluminium salts, which stimulates production of CD4 memory cells following meningococcal B vaccination; and CRM 197, a non-toxic mutant of diphtheria toxin that is used as carrier protein for polysaccharides and haptons to make them immunogenic in conjugate vaccines for several diseases, including meningococcal and pneumococcal infections. Recently he used a genome-based approach, named reverse vaccinology, to discover antigens for a new vaccine against meningococcus B.
Professor Charlotte Watts is Chief Scientific Adviser to the UK Department of International Development (DFID). In this role she is Director of the Research and Evidence Division and Head of the Science and Engineering Profession for DFID. Professor Watts is seconded to DFID from the London School of Hygiene and Tropical Medicine, where she is Professor of Social and Mathematical Epidemiology.

Originally trained as a mathematician, with a Ph.D. in theoretical mathematics from the University of Warwick, she became interested in global health whilst conducting post-doctoral research on the epidemiology of HIV at the University of Oxford. Moving to LSHTM in 1994, after gaining further training in economics and social science, and fieldwork experience in Zimbabwe and other developing countries, she founded the Social and Mathematical Epidemiology Group. The multidisciplinary group uses mathematical, epidemiological and economic research to assess the impact of current and new HIV prevention technologies, and evaluate interventions that tackle the determinants of HIV risk.

Professor Watts is a global expert in violence prevention. She was Senior Technical Advisor to the WHO 10 country population surveys on women’s health and domestic violence; led the systematic review of the global prevalence and health burden of interpersonal violence, and has been senior researcher on 5 cluster randomised controlled intervention trials in sub-Saharan Africa - showing that violence is preventable.

Professor Watts is a Fellow of the Academy of Medical Sciences, and Foreign Associate Member of the US National Academy of Medicine. She has 200 academic publications, and has served on numerous UN technical and Government advisory boards.

Contributor Irin Carmon is a journalist, the bestselling co-author of Notorious RBG, and a frequent speaker around the country. A New York magazine senior correspondent and on-air CNN contributor, she reports and comments on gender, politics, and the law. Carmon and her co-author were featured in the award-winning and Oscar nominated 2018 documentary RBG. The New York Times described Carmon as being "known for her smarts and feminist bona fides. In 2017 and 2018, Carmon teamed up with the Washington Post's investigative team to break the news of sexual harassment and assault allegations against Charlie Rose, as well as CBS's knowledge of his conduct. That work was recognized with a 2018 Mirror Award. She was also a contributing writer to the Post's Outlook section. Carmon previously served as staff reporter focusing on women's rights at MSNBC and NBC News, Salon and Jezebel. Her reporting and commentary has appeared across print, radio, television, and digital platforms. " Of Notorious RBG: The Life and Times of Ruth Bader Ginsburg (2015) which spent three months on the Times' bestseller list, the paper's staff book critic wrote, "That I responded so personally to it is a testimony to Ms. Carmon's storytelling and panache." She speaks frequently across the country on women's leadership and rights. In 2011, she was one of Forbes’ 30 Under 30 in Media. She graduated from Harvard, magna cum laude with highest honors in literature, in 2005. Irin's key topics include: I Dissent: How Ruth Bader Ginsburg Became the Notorious RBG, What’s at Stake for Women at The Supreme Court, Reporting on #MeToo: An Account from the Journalistic Trenches.

Wafaa El-Sadr is the founder and director of ICAP at Columbia University, University Professor of Epidemiology and Medicine and Mathilde Krim-amfAR Professor of Global Health at Columbia University. She established ICAP at the Columbia Mailman School of Public Health, a large Center engaged in the design and implementation of programs in more than 30 countries around the world.

Dr. El-Sadr currently serves as co-principal investigator of the NIH-funded HIV Prevention Trials Network (HPTN) which supports diverse HIV prevention research studies around the world. Her research interests are diverse and include research on the prevention and treatment of HIV, tuberculosis, non-communicable diseases, maternal-child health among others.

She was born in Egypt, received her medical degree from Cairo University, a master’s in public health (in Epidemiology) from Columbia’s Mailman School of Public Health and a master’s in public administration from Harvard University’s Kennedy School of Government. She was named as McArthur fellow in 2008 and is a member of the National Academy of Medicine.
Geoff Garnett works as a Deputy Director at the Bill and Melinda Gates Foundation on improving the effectiveness and sustainability of HIV testing, treatment and prevention programs. Prior to this, Geoff was a Professor at Imperial College London researching the epidemiology, evolution and control of HIV and other sexually transmitted infections. Geoff's work combines mathematical modeling of the transmission dynamics of HIV and STIs and methods of evaluation and uses mathematical models to understand the potential impact, effectiveness, cost-effectiveness and budget impact of interventions. His current research interests include the use of HIV prevention cascades in the planning and monitoring of HIV prevention interventions, understanding the drivers of HIV risk behavior and adoption of prevention interventions, and how targets and indicators can be used to improve HIV interventions.

Dr. Kevin Hybiske is an Assistant Professor in the Division of Allergy and Infectious Diseases at the University of Washington, Seattle, USA. He has adjunct appointments in the Departments of Microbiology and Global Health at the University of Washington. His ongoing research interests concern the pathogenesis of and mechanisms of host manipulation by Chlamydia.

Rena Janamnuaysook is a transgender woman and a health and human rights advocate from Bangkok, Thailand. She works as a program manager for transgender health at the Thai Red Cross AIDS Research Centre, where she established the Tangerine Community Health Center, the first sexual health and well-being clinic for transgender people in the region. Rena also leads the Tangerine Academy for Transgender Health, where she provides technical assistance and capacity building interventions on key population-led health services, including HIV testing, PrEP, Same-Day ART and implementation research to community-based health centers, government partners and private sectors. Rena co-founded the Thai Transgender Alliance, the first transgender-owned human rights organization in Thailand. She received a master’s degree in international development from the University of Birmingham, United Kingdom. Rena currently serves as a board member of the Asia Pacific Transgender Network and the Planned Parenthood Association of Thailand.

Dr. Jørgen Skov Jensen is a consultant physician at SSI where he is heading the Research Unit for Reproductive Microbiology. For more than 25 years, he has been working with mycoplasmas, in particular Mycoplasma genitalium. His current focus is on M. genitalium antimicrobial susceptibility aiming to improve treatment. He has been part of the European STI Guidelines Project Editorial Board since 2006 and was the lead author on the M. genitalium guideline – an area where hard evidence from treatment trials is limited.

Dr. Charlotte Loppie is a Professor in the School of Public Health and Social Policy and Research Lead for the Faculty of Human and Social Development, University of Victoria. Dr. Loppie's research partners have included individual First Nation communities, regional and national Indigenous organizations as well as provincial and national government stakeholders. Dr. Loppie has undertaken research and published in the areas of: Indigenous health, Indigenous HIV/AIDS, social determinants of Indigenous health, racism and cultural safety, Indigenous ethics and research capacity building as well as the sexual and reproductive health of Indigenous women.

Dr. Marra completed residency training in Neurology and fellowship training in Infectious Diseases at the University of Washington, in Seattle, Washington, USA. She is Professor and Vice Chair for Academic Affairs in Neurology, and she has an adjunct appointment in Medicine (Infectious Diseases), at the University of Washington. Dr. Marra directs a US National Institute of Health-funded clinical and translational research program on factors that influence the clinical course of syphilis, with a particular focus on HIV and on neurosyphilis. She received the American Sexually Transmitted Diseases Association Achievement Award in 2014 for work in this area. She also participates in multi-center clinical research on the neurological consequences of HIV, and she provides general neurological care in inpatient and outpatient settings, including a multispecialty HIV clinic.
Johan Melendez, MS, PhD, is a research fellow in the Division of Infectious Diseases at the Johns Hopkins School of Medicine. Dr. Melendez has almost 20 years of experience in the development and evaluation of molecular approaches for characterization of gonorrhea, chlamydia and other infectious agents, and biomarkers of human sexual behavior. His current research focuses on the development, evaluation, and implementation of rapid tests for the diagnosis of STIs and characterization of antimicrobial resistant gonorrhea.

David Peters is an internationally renowned expert in health systems who has worked as a researcher, policy advisor, educator, manager, and clinician in dozens of low and middle-income countries (LMICs). Peters’ work seeks to improve the performance of health systems in LMICs through implementation science, and by building institutional capacity and creating innovations in organization, technology, and financing of health systems. He has published 8 books and monographs, more than 20 book chapters, and over 125 peer-reviewed articles. While working at the World Bank, he pioneered the Sector Wide Approaches (SWAps) in health, which is used by countries to define and implement national strategies and the allocation of foreign aid. In India, he led a research program to examine health systems and inequities, which became the basis for national policies to improve access and financing for health care. In Afghanistan, he created the first nationally implemented Balanced Scorecard to assess and manage health services.

Dr. Poteat is an Assistant Professor of Social Medicine at the University of North Carolina in the Center for Health Equity Research. Her research, teaching, and clinical practice focus on HIV and LGBTQ health with particular attention to the role of stigma in driving health disparities. Certified as an HIV Specialist by the American Academy of HIV Medicine, she is a leader in HIV research and care with transgender persons. She has a special interest in the intersections of gender, sexuality, race, class, and health. Dr. Poteat received a Master of Medical Science degree from Emory University’s Physician Assistant (PA) Program; a Master’s of Public Health from Rollins School of Public Health; and a PhD in the Social and Behavioral Interventions Program in the Department of International Health at Johns Hopkins School of Public Health.

Helena Seth-Smith uses genomic data to investigate bacterial evolution. In her current role within the Division of Clinical Microbiology at the University Hospital Basel, Switzerland, she tries to answer questions relating to emerging pathogens, outbreaks and transmission. An ongoing interest is in sexually transmitted pathogens, having worked for many years on Chlamydia trachomatis (in addition to Chlamydia suis, abortus and pecorum), published cases on sexually transmitted Shigella sonnei, and now exploring diversity and antibiotic resistance in Neisseria gonorrhoeae. She cut her genomic teeth at the Sanger Institute in Cambridge, UK, analysing the genomes of many and varied pathogens. Her PhD at the Institute of Biotechnology, University of Cambridge identified a gene cluster involved in explosive breakdown by Rhodococcus. As bacterial pathogens show no sign of weakening, and STIs will always transmit, she is pleased that she has chosen a fascinating and satisfying career in a field which can only expand.

Rebecca Thurston, PhD. Dr. Thurston is Professor of Psychiatry, Epidemiology, Psychology, and Clinical and Translational Science, and Director of the Women’s Biobehavioral Health Research Program at the University of Pittsburgh. Dr. Thurston’s research interests focus on midlife women's psychosocial experiences, reproductive aging, and cardiovascular health. She takes a biopsychosocial perspective, focusing on exposures prevalent among women and important to their cardiovascular health. As such, Dr. Thurston is Principal Investigator of NIH R01-funded studies on cardiovascular disease and brain aging in women as well as a NIH K24 award supporting interdisciplinary mentoring and training in midlife women's cardiovascular health. For the past 14 years, Dr. Thurston has been an investigator of the Study of Women’s Health Across the Nation, one of the largest multiethnic prospective cohort studies of midlife aging in women. Dr. Thurston is a recipient of the Henry Burger Award from the International Menopause Society, is President Elect of the North American Menopause Society, and is an elected fellow of the Academy of Behavioral Medicine Research.

David Wilson is Program Director in the World Bank’s Health, Population and Nutrition global practice. He leads the World Bank’s Global Solutions Groups in support of Health Systems Strengthening for UHC and also leads a Decision Science initiative focusing on technological innovation. Before joining the Bank in 2003, David worked as an academic, development practitioner and global health advisor for 20 years. David has over published over 100 scientific papers and delivered over 1,000 scientific addresses. He has worked in high- and low-income contexts in over 50 countries on all continents.
Christopher Fairley is the Director of Melbourne Sexual Health Centre, Alfred Health and Professor of Public Health at Monash University. He holds three specialist medical fellowships from the College of Physicians (Infectious Diseases), Faculty of Public Health and Chapter of Sexual Health Medicine, and is a fellow of the Royal College of Physicians and a fellowship of the Australian Academy of Health and Medical Sciences. He is an editor of the Journal 'Sexual Health'. His principle research interests are the public health control of sexually transmitted diseases and the effectiveness of clinical services. He sits on the boards of IUSTI and ISSTDR.

Dr. Handsfield is Professor Emeritus of Medicine, University of Washington. He received his medical degree from Columbia University and served his residency training in internal medicine and fellowship in infectious diseases at the University of Washington. His 40-year career has addressed the clinical aspects, epidemiology, and prevention of STDs. For 25 years he directed the Public Health—Seattle & King County STD Control Program, Seattle, Washington. Dr. Handsfield is former president of ISSTDR and a current IUSTI Senior Counselor, former president of the American Sexually Transmitted Diseases Association, a current member of ASTDA's Executive Committee, an Associate Editor of Sexually Transmitted Diseases, and the 2010 recipient of the ASTDA's Distinguished Career Award (formerly Thomas Parran Award).
<table>
<thead>
<tr>
<th>FIRST NAME</th>
<th>LAST NAME</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oluwafemi</td>
<td>Adeagbo</td>
<td>South Africa</td>
</tr>
<tr>
<td>Michel</td>
<td>Alary</td>
<td>Canada</td>
</tr>
<tr>
<td>Mal</td>
<td>Beale</td>
<td>UK</td>
</tr>
<tr>
<td>Tara</td>
<td>Beattie</td>
<td>UK</td>
</tr>
<tr>
<td>Mariaesa</td>
<td>Becker</td>
<td>Canada</td>
</tr>
<tr>
<td>Adele</td>
<td>Benzaken</td>
<td>Brazil</td>
</tr>
<tr>
<td>Julie</td>
<td>Bettinger</td>
<td>Canada</td>
</tr>
<tr>
<td>James</td>
<td>Blanchard</td>
<td>Canada</td>
</tr>
<tr>
<td>Chris</td>
<td>Bourne</td>
<td>Australia</td>
</tr>
<tr>
<td>Viviane</td>
<td>Bremer</td>
<td>Germany</td>
</tr>
<tr>
<td>Kate</td>
<td>Brookmeyer</td>
<td>USA</td>
</tr>
<tr>
<td>Denton</td>
<td>Calander</td>
<td>Australia</td>
</tr>
<tr>
<td>Caroline</td>
<td>Cameron</td>
<td>Canada</td>
</tr>
<tr>
<td>Allison</td>
<td>Carter</td>
<td>Australia</td>
</tr>
<tr>
<td>Nomathemba</td>
<td>Chandiwana</td>
<td>South Africa</td>
</tr>
<tr>
<td>Xiang-Sheng</td>
<td>Chen</td>
<td>China</td>
</tr>
<tr>
<td>Marcus</td>
<td>Chen</td>
<td>Australia</td>
</tr>
<tr>
<td>Harrell</td>
<td>Chesson</td>
<td>USA</td>
</tr>
<tr>
<td>Admire</td>
<td>Chikandaia</td>
<td>South Africa</td>
</tr>
<tr>
<td>Eric</td>
<td>Chow</td>
<td>Australia</td>
</tr>
<tr>
<td>Frances</td>
<td>Cowan</td>
<td>UK</td>
</tr>
<tr>
<td>Marco</td>
<td>Cusini</td>
<td>Italy</td>
</tr>
<tr>
<td>Alex</td>
<td>de Voux</td>
<td>USA</td>
</tr>
<tr>
<td>Henri</td>
<td>de Vries</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Souléymane</td>
<td>Diabaté</td>
<td>Côte d’Ivoire</td>
</tr>
<tr>
<td>Patricia</td>
<td>Dittus</td>
<td>USA</td>
</tr>
<tr>
<td>Basila</td>
<td>Donovan</td>
<td>Australia</td>
</tr>
<tr>
<td>Mark</td>
<td>Drew</td>
<td>Brazil</td>
</tr>
<tr>
<td>Krista</td>
<td>English</td>
<td>Canada</td>
</tr>
<tr>
<td>Nigel</td>
<td>Field</td>
<td>UK</td>
</tr>
<tr>
<td>Ernst</td>
<td>Fields</td>
<td>USA</td>
</tr>
<tr>
<td>Dennis</td>
<td>Fortenberry</td>
<td>USA</td>
</tr>
<tr>
<td>Jamie</td>
<td>Frankie</td>
<td>UK</td>
</tr>
<tr>
<td>Hongyuan</td>
<td>Fu</td>
<td>USA</td>
</tr>
<tr>
<td>Patricia</td>
<td>Galarza</td>
<td>Argentina</td>
</tr>
<tr>
<td>Patricia</td>
<td>Garcia</td>
<td>Peru</td>
</tr>
<tr>
<td>Suzanne</td>
<td>Garland</td>
<td>Australia</td>
</tr>
<tr>
<td>Charlotte</td>
<td>Gaydos</td>
<td>USA</td>
</tr>
<tr>
<td>Dianne</td>
<td>Gesink</td>
<td>Canada</td>
</tr>
<tr>
<td>Khalil</td>
<td>Ghanem</td>
<td>USA</td>
</tr>
<tr>
<td>Lorenzo</td>
<td>Giaconi</td>
<td>USA</td>
</tr>
<tr>
<td>Jane</td>
<td>Goller</td>
<td>Australia</td>
</tr>
<tr>
<td>Sami</td>
<td>Gottlieb</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Hunter</td>
<td>Handsfield</td>
<td>USA</td>
</tr>
<tr>
<td>Devon</td>
<td>Hensel</td>
<td>USA</td>
</tr>
<tr>
<td>Betsy</td>
<td>Herold</td>
<td>USA</td>
</tr>
<tr>
<td>Jane</td>
<td>Hocking</td>
<td>Australia</td>
</tr>
<tr>
<td>Matthew</td>
<td>Hogben</td>
<td>USA</td>
</tr>
<tr>
<td>Ned</td>
<td>Hook</td>
<td>USA</td>
</tr>
<tr>
<td>Gwenda</td>
<td>Hughes</td>
<td>UK</td>
</tr>
<tr>
<td>Shaiy</td>
<td>Isac</td>
<td>India</td>
</tr>
<tr>
<td>Jorgen</td>
<td>Jensen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Jeff</td>
<td>Jin</td>
<td>Australia</td>
</tr>
<tr>
<td>Christine</td>
<td>Johnston</td>
<td>USA</td>
</tr>
<tr>
<td>Bob</td>
<td>Kiralady</td>
<td>USA</td>
</tr>
<tr>
<td>Patricia</td>
<td>Kissinger</td>
<td>USA</td>
</tr>
<tr>
<td>David</td>
<td>Koelle</td>
<td>USA</td>
</tr>
<tr>
<td>Fabian</td>
<td>Kong</td>
<td>Australia</td>
</tr>
<tr>
<td>Jami</td>
<td>Lechler</td>
<td>USA</td>
</tr>
<tr>
<td>David</td>
<td>Lewis</td>
<td>Australia</td>
</tr>
</tbody>
</table>

| Penny       | Looser    | USA           |
| Sarah       | Lowe      | Zimbabwe      |
| Carla Gianna| Luppi     | Italy         |
| Laxo        | Magnino   | Brazil        |
| Irene       | Martin    | Canada        |
| Philippe    | Mayaud    | UK            |
| Nick        | Medland   | Australia     |
| Supriya     | Mehta     | USA           |
| Hana        | Mijovic    | Canada        |
| Angelica    | Espinosa  | Brazil        |
| Shamimtra   | Mishra    | Canada        |
| Hariss      | Mohammed  | UK            |
| Sinead      | Delany    | Morediw      |
| Christina   | Muzny     | USA           |
| Landon      | Myer      | South Africa  |
| Chinhhinda   | Natsay    | South Africa  |
| Ntendee     | Ndeikoundam| France       |
| Francis     | Ndowa     | Zimbabwe      |
| Trang       | Nguyen    | USA           |
| Abby        | Norris    | Turner       |
| Catherine   | O’Connor  | Australia     |
| Gina        | Ogilvie   | Canada        |
| Jason       | Ong       | UK            |
| Mark        | Pakianathan| UK          |
| Preeti      | Pathela   | USA           |
| Tom         | Peterman  | USA           |
| Nemco       | Peters    | USA           |
| Michael     | Pickles   | Canada        |
| Ravi        | Prakash   | India         |
| Alison      | Quayyle   | USA           |
| BM          | Ramesh    | Canada        |
| Kees        | Rietmeier | USA           |
| Ann         | Rompalo   | USA           |
| Minttu      | Roon      | USA           |
| Jonathan    | Ross      | UK            |
| Tariq       | Sadiq     | UK            |
| Shailendra  | Sawleshwarkar| Australia |
| Euphemia    | Sibanda   | Zimbabwe      |
| Minh        | Skleny    | Czechia       |
| Pam         | Sonnenberg| UK            |
| Ian         | Spicknall | USA           |
| Gianfranco  | Spiteri   | Sweden        |
| Weiming     | Tang      | USA           |
| Amanda      | Tanner    | USA           |
| Memith      | Temple-Smith| Australia   |
| Caroline    | Thng      | Australia     |
| James       | Thomas    | USA           |
| Peter       | Timms     | Australia     |
| Elizabeth   | Torone    | USA           |
| Kat        | Turner    | UK            |
| Anneti      | Uusikuila | Estonia       |
| Birgit      | van Bentheim| Netherlands |
| Rick       | Varn       | Australia     |
| Maria       | Veras      | Brazil        |
| Lenia       | Vodstriel | Australia     |
| Beat        | Huyilesteke| Belgium       |
| Reynold     | Washington| USA           |
| Janet       | Wilson    | UK            |
| Rachel      | Winer     | USA           |
| Gwen        | Wood      | USA           |
| Irina       | Zablotska-Manos| Australia |
| Jonathan    | Zemilman  | USA           |
ASTDA & IUSTI North America
Join the preeminent professional association of STD researchers, practitioners, and prevention specialists in the United States and Canada.

ASTDA AWARDS LUNCHEON
TUESDAY, JULY 16, 12:15-13:45
Distinguished Career Award
Charlotte Gaydos, DrPH, MPH
Achievement Award
Patricia Kissinger, PhD, MPH
Young Investigator Award
Yonatan Grad, MD, PhD

Exclusive Membership Benefits
Joint ASTDA & IUSTI members get benefits from both organizations. These include:
- Free subscription to ASTDA’s journal, Sexually Transmitted Diseases.
- A 40% discount on a subscription to IUSTI’s journal, the International Journal of STD and AIDS.
- Reduced registration fees for the biannual STD Conference and most IUSTI regional and world meetings.

Sexually Transmitted Diseases Journal
- Submit your STD-related manuscripts.
- Read the latest peer-reviewed, original articles on current research.
- Explore the “Real World of STD Prevention,” focused on clinical and prevention practice and the science-to-program interface.

Join TODAY at www.ASTDA.org

SCIENTIFIC PROGRAM (SATURDAY & SUNDAY)

- Career Development Symposium for Emerging Investigators and Program Leaders
  Saturday, July 13
- Pre-Congress Symposia and Opening Keynote
  Sunday, July 14
- Scientific Program
  Monday, July 15
- Scientific Program
  Tuesday, July 16
- Scientific Program
  Wednesday, July 17
- Posters

SATURDAY, JULY 13, 2019
08:45 - 15:30 IUSTI Canada - ASTDA Career Development Symposium for Emerging Investigators and Program Leaders
(By Invitation Only)
Location: MR 11+12

09:00 - 09:20 Introductions
- Marc Steben
09:20 - 10:30 "Speed Intros"
10:30 - 10:45 Coffee Break
10:45 - 11:45 Finding Funding:
- Julie Dombrowski, Industry:
  Scott Gray-Owen
- Aijith Joseph, Abbott
- Courtney Maus, BD
- Hologic
- Chris McGowin, Roche
11:45 - 13:00 Lunch / Career Panel
- Chris L. McGowin, Max Chernesky, Petra Smyczek
13:00 - 14:00 Manuscript Workshop
- Bill Miller
14:00 - 15:00 Small Group Discussions
  - Work-life balance and avoiding burnout: Abigail Norris-Turner
  - How to grow your network/increase visibility: Max Chernesky
  - Thorny issues in collaboration: Julie Dombrowski
  - Balancing clinical, research and teaching: Irene Martin
  - Community engagement, health departments & advisory boards: Marc Steben
15:00 - 15:30 Conclusion and Next Steps

SUNDAY, JULY 14, 2019
PRE-Congress Symposia
09:00 - 16:30 Pre-Congress Symposium 1 - Phase specific strategies for STI and HIV control redux: Resurgence, concentrations, networks, key populations, and magic bullets
Location: MR 11+12

09:15 - 09:35 STI/HIV prevention today
- Sevgi Aral, Centers for Disease Control and Prevention, USA

09:35 - 10:05 Background and progress in phase-specific strategies
- Judy Wasserheit, University of Washington, USA

10:05 - 10:35 Emerging research methods and collaborations to improve program design and implementation
- Geoff Garnett, Bill & Melinda Gates Foundation, USA
11:00 - 11:30  Appraising epidemic phases and transmission dynamics – insights from epidemiology and mathematical modeling
  - Sharmistha Mishra, University of Toronto, Canada
11:30 - 12:00  ART-based prevention: Observations on the pathway from efficacy to effectiveness
  - Myron Cohen, University of North Carolina, USA
12:00 - 12:30  Round table discussion – what have we learned from modeling about targeting for HIV prevention, and what more do we need to learn?
13:30 - 14:00  How can we improve resource allocation and management in the changing global HIV Landscape?
  - David Wilson, World Bank, USA
14:00 - 14:30  HIV and STI prevention program design: Back to the basics
  - James Blanchard, University of Manitoba, Canada
14:45 - 15:15  Challenges in the implementation of new interventions for HIV/STI
  - Helen Ward, Imperial College London, UK
15:15 - 15:45  Phase shifts in HIV and STI epidemics in Sub-Saharan Africa: Implications for programs and science
  - Richard Hayes, London School of Hygiene & Tropical Medicine, UK
15:45 - 16:15  Round table discussion - phase specific strategies and future priorities for program science
16:15 - 16:30  Wrap-up • Concluding Remarks
  - Sevgi Aral

Pre-Congress Symposium 2 - The global challenges and opportunities of STIs in pregnancy
Location: MR 2+3
Organized by University of California Los Angeles
08:00 - 08:10  Welcome
  - Jackie McDowell, Cepheid
08:10 - 08:30  Overview
  - Jeffrey D Klausner, UCLA - David Geffen School Of Medicine, Los Angeles, USA
08:30 - 08:55  Curable STIs in pregnant women living in Brazil: A challenge ripe for intervention
  - Nava Yeganeh, University of California, Los Angeles, USA
08:55 - 09:20  Syndromic management for STIs during pregnancy just doesn’t cut it anymore: Implementing diagnostic screening to reduce adverse birth outcomes in South Africa
  - Andrew Medina-Marino, Foundation of Professional Development, South Africa
09:20 - 09:45  Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-income settings: The WANTAiM Trial, Papua New Guinea
  - Andrew Vallely, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea & The Kirby Institute, UNSW Sydney, Australia
09:45 - 10:10  Antenatal Chlamydia trachomatis and Neisseria gonorrhoeae testing compared to syndromic management in Botswana: A cost-effectiveness study
  - Adriane Wynn, University of California, San Diego, USA
10:20 - 10:45  Chlamydia trachomatis screening and treatment among pregnant women in China: Evidence and challenges
  - Weiming Tang, University of North Carolina at Chapel Hill, USA

10:45 - 11:20  The ASPIRE Trial – aiming for safe pregnancies: Reducing malaria and infections of the reproductive tract in Zambia
  - Matthew Chico, London School of Hygiene & Tropical Medicine, United Kingdom
11:10 - 11:35  Enhancing nutrition and antenatal infection treatment for maternal and child health (ENAT) study: Screening and treating genitourinary tract infections to improve birth outcomes in Amhara, Ethiopia
  - Rose L. Molina, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

11:35 - 12:00  Summary and next steps
  - Nicola Low, Institute of Social and Preventive Medicine, University of Bern, Switzerland

Pre-Congress Symposium 3 - Understanding variability and improving the reproducibility of genital microbiome research
Location: MR 1
Chair: Jen Balkus, University of Washington, USA
08:00 - 08:15  Introductions and motivations for the Vaginal Microbiome Laboratory Variability Project (MLVP)
  - Jen Balkus, University of Washington, USA
08:15 - 08:30  Overview of the Vaginal Microbiome Laboratory Variability Project
  - David Fredricks, Fred Hutchinson Cancer Research Center, USA
08:30 - 09:00  Laboratory challenges and opportunities to reduce variability: Lessons learned from the MLVP
  - Sujatha Srinivasan, Fred Hutchinson Cancer Research Center, USA
  - Darrell Dinwiddie, University of New Mexico, USA
09:00 - 09:30  Bioinformatics challenges and opportunities to reduce variability: Lessons learned from the MLVP
  - Johanna Holm, University of Maryland, USA
  - Liam Van Der Pol, University of Alabama, USA
10:00 - 10:20  Statistical analyses and challenges for assessing variability
  - Jim Hughes, University of Washington, USA
  - Pawel Gajer, University of Maryland, USA
10:20 - 10:40  Successes and challenges of implementing the MLVP and opportunities to improve reproducibility moving forward
  - Jacques Ravel, University of Maryland, USA
10:40 - 11:30  Round table discussion with other experts engaged in vaginal microbiome research
  - Carolyn Deal, NIAUD/DMD, USA
  - Jennifer Fettweis, VCU, USA
  - Doug Kwon, Ragon Institute, USA
  - Deborah Money, UBC, Canada

Pre-Congress Symposium 4 - Shaking the trees: Optimizing treatment and antimicrobial stewardship for STIs
Location: MR 1
Facilitators: Laura Bachmann, MD, MPH - Medical Director, CDC Division of STD Prevention & Christine Johnson, MD, MPH - Associate Professor, University of Washington at Seattle; Medical Director, University of Washington STD Prevention Training Centers
Talk 1. Global STI trends and priorities for antimicrobial resistance
  - Tedorea Elvira Wi, STI Department of Reproductive Health and Research, World Health Organization, Switzerland
Pre-Congress Symposium 5 - The resurgence of syphilis: What have we learned and how can we respond?

Location: MR: 8+15

Organized by David Lewis and Gwenda Hughes

Refreshments supported by Western Sydney Sexual Health, University of Sydney, Australia

08:00 - 08:10 Welcome and Introduction
- David Lewis, University of Sydney, Australia

08:10 - 08:30 Syphilis: A historical overview
- David Lewis, University of Sydney, Australia

08:30 - 09:00 Keynote lecture: Syphilis: What we know and what we need to know
- Sheila Lukehart, University of Washington, USA

09:00 - 09:20 The application of modern technologies to the goal of syphilis elimination
- Caroline Cameron, University of Victoria, Canada

09:20 - 09:40 What can we learn about syphilis from whole genome sequencing of global Treponema pallidum strains
- Nick Thomson, Sanger Institute, UK

09:40 - 10:00 Syphilis in the context of HIV co-infection
- Khalil Ghanem, Johns Hopkins University, USA

10:00 - 10:20 Syphilis, the great imitator: Unusual case presentations of syphilis in adults
- Somesh Gupta, All India Institute of Medical Sciences, India

10:40 - 11:00 Recent trends in syphilis in women and congenital syphilis in developed countries: A changing epidemiology?
- Gwenda Hughes, Public Health England, UK

11:00 - 11:20 Drivers and determinants for the rising incidence of syphilis in men-who-have-sex-with-men
- Kyle Bernstein, Centers for Disease Control and Prevention, USA

11:20 - 11:40 Responding to syphilis in China: The importance of key populations
- Xiang-Sheng Chen, National Center for STD Control, China

11:40 - 12:00 Syphilis control efforts and public health policy: Global perspectives
- Francis Ndowa, Skin & GU Medicine Clinic, Harare, Zimbabwe

Pre-Congress Symposium 6 - The role of brief behavioural interventions in a combination prevention approach to sexually transmitted infections, including HIV

Location: MR 7

PART I - SRH behavioural interventions Global State of Affairs

Co-chairs:
- Igor Toskin, World Health Organization, Switzerland
- King Holmes, Dept. of Global Health & Medicine, University of Washington, USA
- Carmen Logie, University of Toronto, Canada

08:00 - 08:20 WHO perspective on behavioural interventions
- Igor Toskin, World Health Organization, Switzerland

08:20 - 08:40 Exploring the landscape of behavioural HIV/STI prevention interventions in Canada
- Carmen Logie, University of Toronto, Canada

08:40 - 09:00 Scientific evidence of effectiveness of behavioural interventions for shifting sexual health outcomes
- Rob Stephenson, Center for Sexuality and Health Disparities, University of Michigan, USA

09:00 - 09:20 Delivering behavioural interventions through e-health and mHealth technologies
- Keith Horvath, University of Minnesota, USA

09:40 - 10:00 Screening of a behavioural intervention using Motivational Interviewing (MI)

PART II - Country perspectives behavioural interventions and WHO Brief Sexuality-related Communication (BSC) feasibility study

Co-chairs:
- Igor Toskin, World Health Organization, Switzerland
- King Holmes, Dept. of Global Health & Medicine, University of Washington, USA
- Carmen Logie, University of Toronto, Canada

08:00 - 08:20 WHO perspective on behavioural interventions
- Igor Toskin, World Health Organization, Switzerland

08:20 - 08:40 Exploring the landscape of behavioural HIV/STI prevention interventions in Canada
- Carmen Logie, University of Toronto, Canada

08:40 - 09:00 Scientific evidence of effectiveness of behavioural interventions for shifting sexual health outcomes
- Rob Stephenson, Center for Sexuality and Health Disparities, University of Michigan, USA

09:00 - 09:20 Delivering behavioural interventions through e-health and mHealth technologies
- Keith Horvath, University of Minnesota, USA

09:40 - 10:00 Screening of a behavioural intervention using Motivational Interviewing (MI)
08:00 - 12:00
Pre-Congress Symposium 7 - Ibero-American Network on Gay Men, others MSM and Trans Studies (RIGHT) and the Latin American Men Who Have Sex With Men Internet Survey (LAMIS)
Location: MR 13

Talk 1. The Ibero-American network on gay men, others MSM and trans studies (RIGHT)
- Valeria Stuardo Ávila, Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Santiago, Chile

Talk 2. The methodological framework of Latin American men who have sex with men internet survey (LAMIS) in light of the prior EMIS studies
- Ulrich Marcus, Robert Koch Institute, Berlin, Germany

Talk 3. Implementation of LAMIS as a collaborative effort in Latin American countries
- Carlos Cáceres, Centro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru

Talk 4. General results - descriptive analysis of LAMIS 2018: Implications for collaborative public policies in the Latin American region
- Jordi Casabona, Centre d'EstudisEpidemiològics sobrelesInfeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Barcelona, Spain

Talk 5. HIV among MSM and TGW in Brazil: Different approaches, same striking results
- Maria Amélia Veras, Faculdade de Ciências Médicas daSanta Casa de São Paulo, Núcleo de Pesquisa em Direitos Humanos e Saúde LGBT, Brazil

08:00 - 12:00
Pre-Congress Symposium 8 - The next frontier of treatment and prevention of sexually transmitted infections: Expedited partner therapy use in heterosexuals, adolescents, men who have sex with men, and transgender women
Location: MR 14

Talk 1. Expedited partner therapy
- Okeoma Mmeje, University of Michigan, USA

Talk 2. MPH expedited partner therapy use in heterosexuals
- Jenell Coleman, Johns Hopkins University, USA

Talk 3. Expedited partner therapy use in adolescents & school-based clinics
- Nicole Speck, University of Michigan, USA

Talk 4. Support for expedited partner therapy use in men who have sex with men & transgender women
- Kristi Gamarel, University of Michigan, USA
- Raha Richardson, University of Michigan, USA

Talk 5. Implications for expedited partner therapy use in men who have sex with men
- Julia Schillinger, Centers for Disease Control and Prevention, USA

13:00 - 17:00
Pre-Congress Symposium 9 - Highlights of selected topics from the Canadian STI guidelines
Location: MR 8+15
Chair(s): Max Cherneshky, McMaster University, Canada
Margaret Gale-Rowe, PHAC, Canada

13:00 - 13:30  Mycoplasma genitalium
- Annie-Claude Labbe, Université de Montréal, Canada

13:00 - 14:00  Gonorrhea: Approach to management in the setting of rising antimicrobial resistance
- Ameeta Singh, University of Alberta, Canada

14:00 - 14:30  Prenatal screening for STBBIs
- Mark Yudin, University of Toronto, Canada

13:00 - 17:00
Pre-Congress Symposium 10 - IUSTI Canada Symposium: Innovative platforms and interventions against gonorrhoea
Location: MR 8+15

Talk 1. International dissemination of ceftriaxone-resistant Neisseria gonorrhoeae strain (FC428)
- Petra Smyczek, Alberta Health Services, Edmonton, Alberta, Canada

Talk 2. What’s new in gonococcal antimicrobial resistance and diagnosis of AMR
- Jo-Anne Dillon, Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Canada

Talk 3. New anti-gonococcal antibiotics, discovery and pipeline
- Gerry Wright, McMaster University, Hamilton, Ontario, Canada

Talk 4. Almost Human: Advanced preclinical models for gonococcal vaccine and drug development
- Scott Gray-Owen, University of Toronto, Toronto, Ontario, Canada

13:00 - 17:00
Pre-Congress Symposium 11 - Proteomics
Location: MR 14
Chair: Leonard Foster, UBC, Canada

Talk 1. Metaproteomics for discovering mechanisms and biomarkers in the vaginal microbiome
- Adam Burgener, University of Manitoba, Canada

Talk 2. Towards the development of a SISCAPA assay for direct measurement of T. pallidum proteins in bodily fluids
- Morty Razavi, SISCAPA Assay Technologies (SAT), Canada

Talk 3. When and how to bring in proteomics
- Leonard Foster, UBC, Canada

Talk 4. Practical considerations for moving proteomic tests into the clinic
- Angela Fung, Clinical Chemist, St. Paul’s Hospital, Vancouver, Canada

13:00 - 17:00
Pre-Congress Symposium 12 - Sexually transmitted infection vaccines - opportunities for research, development and implementation
Location: MR 1
Opening remarks:
- Troy Grennan & Monika Naus, University of British Columbia & the BC Centre for Disease Control, Canada
**Pre-Congress Symposium 13 - Accelerating development and implementation of point-of-care tests for sexually transmitted infections: Challenges, achievements, and way forward**

**Location:** MR 9

**PART I - STI POCT Global State of Affairs**

**Chair(s):**
- Igor Toskin, World Health Organization, Switzerland
- Rosanna Peeling, London School of Hygiene and Tropical Medicine, United Kingdom

- 13:10 - 13:25 The current landscape of STI vaccines
  - Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA

- 13:25 - 13:40 STI vaccine roadmap
  - Sami Gottlieb, World Health Organization, Switzerland

- 13:40 - 13:55 Will the world accept STI vaccines? Lessons from the HPV vaccine
  - Simon Dobson, University of British Columbia, Canada

- 13:55 - 14:55 STI vaccine development updates: Current science and future directions
  - Syphilis: Caroline Cameron, University of Victoria, Canada
  - Gonorrhea: Rino Rappuoli, GSK Vaccines, Italy
  - Chlamydia: Kevin Hybiske, University of Washington, USA
  - HSV: Anna Wald, University of Washington, USA

- 15:10 - 15:55 Priority setting for future science & research (panel discussion)
  - Moderated by: Scott Lamontagne, University of Washington, USA
  - Caroline Cameron, University of Victoria, Canada
  - Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA
  - Rino Rappuoli, GSK Vaccines, Italy
  - Peter Dull, Bill & Melinda Gates Foundation

- 15:55 - 16:40 Implementation challenges in public health (panel discussion)
  - Moderated by: Scott Lamontagne, University of Washington, USA
  - Sami Gottlieb, World Health Organization, Switzerland
  - Bonnie Henry, Government of British Columbia, Canada
  - Manish Sadarangani, Vaccine Evaluation Centre, Canada
  - Peter Dull, Bill & Melinda Gates Foundation

**Closing remarks:**
- Manish Sadarangani, Vaccine Evaluation Centre, Canada
- Gina Ogilvie, School of Population and Public Health (SPPH), Canada

**Pre-Congress Symposium 14 - Preparing Sexual Health Services for Antimicrobial Resistance Bacteria: A Global Perspective**

**Location:** MR 2+3

**Organizing committee:** Dr Katy Turner, Prof Nicola Low, Dr Yonatan Grad, Prof Teodora Wi, Prof Magnus Unemo, Dr Minttu Ronn

- 14:10 - 14:25 Rapid AMR-test technology to enable immediate accurate treatment and enhance AMR surveillance
  - Tariq Sadiq, St George’s University of London, United Kingdom

- 14:25 - 14:35 Sample self-collection and STI self-testing
  - Ellen Kersh, Centers for Disease Control and Prevention (CDC), Atlanta, USA

**PART II - Country Perspective and Current WHO STI POCT Evaluation Studies**

**Chair(s):**
- Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
- Ron Ballard, World Health Organization, Switzerland

- 14:55 - 15:40 Independent multi-country clinic-based evaluation of STI POCTs: Study design, methodology, research instruments, data management system and current status
  - Soe Soe Thwin, World Health Organization, Switzerland
  - Massimo Miranda, University of Verona, UoV, Italy
  - Karel Blondeel, World Health Organization, Switzerland

- 15:40 - 16:00 Independent multi-country clinic-based evaluation of STI POCTs: internal quality control and external quality assurance:
  - NG/CT/TV: Ellen Kersh, Centers for Disease Control and Prevention (CDC), Atlanta, USA
  - HSV: Kelly Andrewartha, Flinders University, Adelaide, Australia
  - Syphilis: Sami Gottlieb, World Health Organization, Switzerland

- 16:00 - 16:15 Independent multi-country clinic-based evaluation of STI POCTs: implementation in selected sites:
  - Italy: challenges and opportunities in piloting the study procedures and engaging with MSM in an outpatient setting
  - Maddalena Cordioli, University of Verona, UoV, Italy
  - South Africa: Current status, programmatic needs and challenges
  - Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
  - Peru
  - Carlos Cáceres, Universidad Peruana Cayetano Heredia, Peru

- 16:35 - 16:45 Independent multi-country clinic-utility evaluation of STI POCTs: utility and engaging with MSM in an outpatient setting
  - Perona Peeling, London School of Hygiene and Tropical Medicine, United Kingdom

**Closing remarks:**
- Peter Dull, Bill & Melinda Gates Foundation
- Maddalena Cordioli, University of Verona, UoV, Italy
- South Africa: Current status, programmatic needs and challenges
- Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
- Peru
- Carlos Cáceres, Universidad Peruana Cayetano Heredia, Peru

**Pre-Congress Symposium 14 - Preparing Sexual Health Services for Antimicrobial Resistance Bacteria: A Global Perspective**

**Location:** MR 2+3

**Organizing committee:** Dr Katy Turner, Prof Nicola Low, Dr Yonatan Grad, Prof Teodora Wi, Prof Magnus Unemo, Dr Minttu Ronn

- 13:00 Session 1 - Setting the scene

**Talk 1. WHO perspectives on the threat of AMR – global challenges of surveillance**
- Teodora Wi, World Health Organization, Switzerland
SCIENTIFIC PROGRAM [SUNDAY]

Pre-Congress Symposium 15 - Understanding the costs and benefits of sexual health services and interventions: A guide for clinicians and researchers

Location: MR 13
Organized by Dr Louise Jackson

13:00 - 17:00

13:00 13:15 The economics of sexual health services and interventions – a service perspective
- Jonathan Ross, University of Birmingham, UK

13:15 14:00 Overview of key principles in analysing costs and benefits in Sexual Health
- Tracy Roberts, University of Birmingham, UK

14:00 14:45 A practical guide to collecting and analysing data on costs and benefits
- Louise Jackson, University of Birmingham, UK

15:00 16:00 Activity – analysing an economic study

16:00 16:40 Workshop – developing an evaluation

16:40 17:00 Synthesis & next steps
- Jonathan Ross, University of Birmingham, UK
- Tracy Roberts, University of Birmingham, UK

LOCATION: BALLROOM

Welcome Ceremony
17:30 - 18:30
Chairpersons: Caroline Cameron, ISSTDR President and Congress President, and Charlotte Gaydos, IUSTI President and Congress Co-President

K01 Opening Keynote Lecture
18:30 - 19:30
Chairpersons: Caroline Cameron, President, International Society for Sexually Transmitted Diseases Research, University of Victoria, Canada and Henry de Vries, STI & HIV 2021 World Congress President, Amsterdam University Medical Centers, The Netherlands
2019 ISSTDR PRESTIGIOUS LECTURE: BACTERIAL STI VACCINES - ETERNAL DREAM OR FUTURE REALITY?
- Rino Rappuoli, GSK Vaccines, Italy

Welcome Reception
19:30 - 21:00
Location: Exhibit Hall A
Key to tracks (colours)

- Basic Science & Translational Research (BSTR)
- Clinical Science (CS)
- Epidemiology & Monitoring (EM)
- Behavioural & Social Science (BSS)
- Policy & Community Engagement (PCE)
- Program & Implementation Science (PIS)
- Special Symposia

Monday, July 15, 2019

07:00 - 08:00

CCS01 Clinical Case Series - Syphilis: The great imitator
Location: MR 8+15
Chairpersons: Stephanie Cohen, San Francisco Department of Public Health, USA and Khalil Ghanem, Johns Hopkins University, USA

CCS01.1 Neurosyphilis is more common among malignant syphilis: Based on case series evidence
- Pingyu Zhou, Shanghai Skin Disease Hospital, China

CCS01.2 A case series of syphilis masquerading as thoracic malignancy
- Jessica Doctor, Guys’ and St Thomas’s NHS Foundation Trust, UK

CCS01.3 Syphilis as fibromyalgia with unexplained hepatosplenomegaly
- Jackie Sherrard, Buckinghamshire Healthcare NHS Trust, UK

08:15 - 08:50

PL01.1 Plenary 1
Chairperson: Sheila Lukehart, University of Washington, USA
The role of genomics in the diagnosis and management of STIs
Helena Seth-Smith, University Hospital Basel, Switzerland

08:50 - 09:25

PL02.1 Plenary 2
Chairperson: Edward Hook, University of Alabama at Birmingham, USA
Identification and management of complicated syphilis
Christina Marra, University of Washington, USA

09:25 - 10:00

PL03.1 Plenary 3
Chairperson: James Ward, South Australian Health and Medical Research Institute, Australia
Engaging indigenous communities in health programs
Charlotte Loppie, University of Victoria, Canada

10:00 - 10:15

Welcome by Elder, Coast Salish Nations
Chairperson: Mark Gilbert, BCCDC, Canada

10:15 - 10:45

Coffee Break
Location: Exhibit Hall A

10:45 - 12:15

S01 Symposium 1
Program science/implementation science methods: Moving beyond the traditional RCT
Chairpersons: Nicola Low, Institute of Social and Preventative Medicine, Switzerland and Marissa Becker, University of Manitoba, Canada
Location: MR 11+12

S01.1 Must the evaluation of complex interventions be complex? Learning from the impact evaluation of DREAMS
- Isolde Birdthistle, The London School of Hygiene & Tropical Medicine, UK

S01.2 HPTN 071 (PopART): Findings and lessons from a non-traditional RCT
- Richard Hayes, The London School of Hygiene & Tropical Medicine, UK

S01.3 Using multiple data sources for program evaluation: Integration of program monitoring data with other research studies
- Banadakoppa Ramesh, University of Manitoba, Canada

S01.4 Evaluating complex public health issue violence - understanding and measuring violence and evaluating violence interventions - lessons from STRIVE
- Sinead Delany-Morette, Wits Reproductive Health and HIV Institute, South Africa

S02 Symposium 2
HIV and syphilis self-testing and self-collection: Empowerment, agency and implementation
Chairpersons: Judith Wasserheit, University of Washington, USA and Adele Schwartz Benzaken, Tropical Medicine Foundation, Brazil
Location: MR 1

S02.1 HIV self-testing in Eastern and Southern Africa: The STAR project
- Maryam Shahmanesh, Institute for Global Health, University College London, UK

S02.2 Syphilis self-testing: A nationwide pragmatic study among men who have sex with men in China
- Cheng Wang, Southern Medical University, China

S02.3 HPV self-collection in Peru: Project HOPE
- Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru

S02.4 Empowerment and approaches for stigma reduction: Implementation of HIV self-testing among female sex workers
- Catherine Oldenburg, University of California, San Francisco, USA

S03 Symposium 3
Epidemiological aspects of STI transmission in MSM
Chairpersons: Gwenda Hughes, Public Health England, UK and Maarten Schim van der Loef, Center for Infection and Immunity Amsterdam, Academic Medical Center, Amsterdam, The Netherlands
Location: Ballroom

S03.1 Impact of HIV PrEP on risk compensation and STI epidemiology – what does the evidence show?
- Helen Ward, Imperial College London, UK

S03.2 The role of oral-anal transmission in persistence of chlamydial infection
- Henry de Vries, University of Amsterdam, Netherlands

S03.3 Sexual transmission of N. meningitidis in MSM and implications for public health
- Anna McNulty, Sydney Sexual Health Centre, Australia

S03.4 Hepatitis C in HIV-negative MSM – a growing concern?
- Axel J. Schmidt, London School of Hygiene & Tropical Medicine, UK
S04 Symposium 4
The impact of advances in diagnostic technology on policy, program and practice (ISSDR Special Symposium)
Chairpersons: Barbara van der Pol, University of Alabama at Birmingham, USA and Rosanna Peeling, London School of Hygiene & Tropical Medicine, UK
Location: MR 2+3

S04.1 Resistance-guided therapy for M. genitalium: Impact of diagnostic resistance assays on practice and policy
- Catriona Bradshaw, Central Clinical School, Monash University, Australia

S04.2 Point of care and home testing opportunities: Implications for quality public health practice
- Patricia Dittus, Centers for Disease Control and Prevention, USA

S04.3 Home based testing: Unintended consequences and implications for antimicrobial stewardship – should we be concerned?
- Paddy Horner, Population Health Sciences, University of Bristol, UK

S04.4 Implementing molecular testing to predict Neisseria gonorrhoeae susceptibility in clinical practice
- Jeffrey D. Klausner, UCLA - Geffen School Of Medicine, USA

O01 Oral Presentation Session 1
Development of vaccines for bacterial STIs
Chairpersons: Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA and Kate Seib, Griffith University, Australia
Location: MR 8+15

O01.1 Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine
- Henju Marjuki, Centers for Disease Control and Prevention, USA

O01.2 Genetic, structural, and surface antigenic variation of Treponema pallidum's OMPeome: Steps towards a global syphilis vaccine
- Kelly Hawley, Connecticut Children's Medical Center, USA

O01.3 Engineering hybrid bacterial transferrin receptor-based vaccines to confer broad protection against Neisseria gonorrhoeae
- Scott Gray-Owen, University of Toronto, Canada

O01.4 Rabbit immunization with B. burgdorferi expressing T. pallidum TprK and Tp0435 as a novel vaccine design for syphilis
- Lorenzo Giacani, University of Washington, USA

O01.5 A meningococcal native outer membrane vesicle vaccine as a platform for presenting conserved gonococcal antigens
- Gregory Moe, UCSF Benioff Children's Hospital Oakland, USA

O01.6 Meningococcal vesicle vaccines deleted for major outer membrane proteins enhance gonococcal clearance in a murine model
- Kathryn Matthias, US Food and Drug Administration, USA

O02 Oral Presentation Session 2
Extragenital bacterial STIs: Epidemiology, natural history, testing and antimicrobial resistance
Chairpersons: Jackie Sherrard, Bucks Healthcare NHS Trust, UK and Remco Peters, Anova Health Institute and University of Pretoria, South Africa
Location: MR 13

O02.1 What Is the optimal testing strategy for oropharyngeal Neisseria gonorrhoeae in women visiting STI clinics?
- Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), The Netherlands

O02.2 Oropharyngeal and genital gonorrhoea among heterosexuals who report sexual contact with partners with gonorrhoea
- Eric Chow, Monash University, Australia

O02.3 Antimicrobial resistance in pharyngeal Neisseria gonorrhoeae infection: A cross-sectional study in men who have sex with men
- Hester Allen, Public Health England, UK

O02.4 Incidence and duration of pharyngeal and rectal gonorrhoea and chlamydia among high-risk men who have sex with men (MSM)
- Lindley Barbee, University of Washington, USA

O02.5 Inflammatory cytokines in rectal gonorrhea/chlamydia infection and treatment: Towards STI control as HIV prevention for MSM
- Jesse Clark, UCLA Geffen School of Medicine, USA

O02.6 Extragenital Mycoplasma genitalium infections amongst men who have sex with men
- Rosie Latimer, Monash University, Australia

S04.1 10:45 - 12:15
S04.2 12:15 - 13:45

O03 Oral Presentation Session 3
Persistence and resistance
Chairpersons: Anna Maria Geretti, University Of Liverpool, UK and Ranmini Kularatne, National Institute for Communicable Diseases, South Africa
Location: MR 9

O03.1 Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection
- Christine Johnston, University of Washington, USA

O03.2 Detection of glycosylated Treponema pallidum proteins: Relevance for diagnostic assays and importance for infection
- Alloysius Gomez, University of Victoria, Canada

O03.3 The European gonococcal antimicrobial surveillance programme findings 2017
- Michaela Day, Public Health England, UK

O03.4 Modelling intervention strategies for preventing spread of extensively drug resistant gonorrhoea strains among Australian MSM
- Qibin Duan, University of New South Wales, Sydney, Australia

O03.5 Utility of real-time whole genome sequencing in partner notification and control of Neisseria gonorrhoea infection
- Ling Yuan Kong, Leeds Teaching Hospitals NHS Trust, UK

O03.6 Vaginal bacteria and risk of incident and persistent infection with high risk sub-types of human papillomavirus
- Kayla Carter, University of Washington, USA

Break

LOCATION: BALLROOM

PL04.1 Plenary 4
Chairperson: Janet Wilson (IUSTI President-Elect), Leeds Teaching Hospitals NHS Trust, UK

2019 IUSTI Prestigious Lecture - Revising STI treatment guidelines in times of rapidly evolving antimicrobial resistant STIs
Jørgen Jensen, Statens Serum Institut, Denmark
SCIENTIFIC PROGRAM (MONDAY)

14:20 - 14:55
PL05.1 Plenary 5
Chairperson: Maria Amelia de Sousa Mascena Veras, Faculdade De Ciências Médicas Da Santa Casa De São Paulo, Brazil
Priorities for research and programmes for trans communities
Tonia Poteat, University of North Carolina, USA

14:55 - 15:30
PL06.1 Plenary 6
Chairperson: Sevgi Aral, CDC, USA
Mathematical modelling, a luxury or a necessity in STD control?
Geoff Garnett, Bill & Melinda Gates Foundation, USA

15:30 - 16:15
Coffee Break
Location: Exhibit Hall A

16:15 - 17:45
S05 Symposium 5
Community engagement, mobilization and empowerment
Chairpersons: Maryam Shahmanesh, Institute for Global Health, University College London, UK and Igor Toskin, WHO, Switzerland
Location: MR 2+3

S05.1 Working with community to control HIV/STI: A U.S. local health department perspective
- Matthew Golden, University of Washington, USA

S05.2 Mobilising for health and rights: A history of sex worker activism in India
- Smarajit Jana, Sonagachi Research and Training Institute, India

S05.3 Mobilization and empowerment of sex workers: Can self-help groups bring about sustained change?
- Primrose Matambanadzo, CeSHHAR, Zimbabwe

S05.4 #SaveSexy: A gamified approach to harnessing the power of community activism for HIV testing promotion
- Benedict Bernabe, Red Whistle, Philippines

16:15 - 17:45
S06 Symposium 6
Improved models and tools for STI infections
Chairpersons: Nicholas Thomson, Wellcome Sanger Institute, UK and Lorenzo Giacani, University of Washington, USA
Location: MR 9

S06.1 Use of cervical explants to study gonococcal pathogenesis
- Daniel Stein, University of Maryland, USA

S06.2 Bringing culture to the uncultured: Long-term culture of the syphilis spirochete, Treponema pallidum
- Steven Norris, University of Texas, USA

S06.3 Pigtailed macaque model of STIs
- Dorothy Patton, University of Washington, USA

S06.4 Chlamydia, trichomonas and syphilis infections in macaques: Effects on simian HIV acquisition
- Sundaram Ajay Vishwanathan, Center for Disease Control and Prevention, USA

16:15 - 17:45
O04 Oral Presentation Session 4
Antimicrobial resistance in STI pathogens
Chairpersons: Jo-Anne Dillon, University Of Saskatchewan, Canada and Tariq Sadig, St George's, University of London, UK
Location: MR 1

O04.1 Novel pathway to ceftriaxone resistance in clinical isolates of N. gonorrhoeae via point mutations in the RNA polymerase
- Yonatan Grad, Harvard T.H. Chan School of Public Health, USA

O04.2 Phylogenomic analysis reveals persistence of Neisseria gonorrhoeae clades with reduced susceptibility to cephalosporins
- Jesse Thomas, US Centers for Disease Control and Prevention, USA

O04.3 Prioritizing novel drug targets based on genomics and proteomics approach in Neisseria gonorrhoeae
- Daman Saluja, University of Delhi, India

O04.4 Mycoplasma genitalium parC and gyrA mutations associated with moxifloxacin and sitafloxacin treatment failure
- Gerald Murray, The Royal Women's Hospital, Australia

O04.5 Point-of-care magnetofluidic assay cartridge for Neisseria gonorrhoeae detection and antimicrobial resistance determination
- Alexander Trick, Johns Hopkins University, USA

O04.6 Prediction of available drug targets of Neisseria gonorrhoeae based on codon usage parameter
- Umra Chaudhry, Bhaskaracharya College of Applied Sciences, University of Delhi, India

16:15 - 17:45
S07 Symposium 7
Sexual health at the intersection of substance use and social inequality
Chairpersons: Mark Pakianathan, The London School of Hygiene & Tropical Medicine, UK and Vincent Cornelisse, Kirketon Road Centre, Australia
Location: Ballroom

S07.1 The North American overdose crisis: How structural violence, prohibition and stigma have paralyzed our response
- Mark Tyndall, BC Centre for Disease Control, Canada

S07.2 Chemsex and new STI/HIV diagnoses among gay, bisexual and other men who have sex with men attending sexual health clinics
- Aseel Hegazi, St George's University Hospital Foundation Trust, UK

S07.3 Challenges in defining Chemsex. Answers for surveillance from EMIS-2017
- Axel Schmidt, London School of Hygiene & Tropical Medicine, UK

S07.4 Review of sexualized drug use associated with sexually transmitted infections (STI) in men who have sex with men (MSM)
- Fiona Guerra, Public Health Ontario, Canada

16:15 - 17:45
O05 Oral Presentation Session 5
Female genital infections, immunology and microbiome
Chairpersons: Rebecca Brotman, University of Maryland School of Medicine, USA and Yaw Adu Sarkodie, Kwame Nkrumah University of Science and Technology, Ghana
Location: MR 13

O05.1 Lower genital tract predictors of acute endometritis among women with signs and symptoms of pelvic inflammatory disease (PID)
- Sharon Hillier, University of Pittsburgh and Magee-Womens Research Institute, USA
005.2 Characterizing the impact of penile-vaginal sex on HIV-susceptible CD4+ T Cell subsets in the female genital tract
- Avid Mohammadi, University Of Toronto, Canada

005.3 The combined contraceptive vaginal ring increases Th17-related cytokines in the genital tract: A randomized crossover trial
- Ilayoo Konstantinou, University of Cape Town, South Africa

005.4 The effect of the combined oral contraceptive pill on the vaginal microbiota of women treated for bacterial vaginosis
- Larissa Ratten, Monash University, Australia

005.5 A case control study to examine the cervico-vaginal microbiota associated with pelvic inflammatory disease
- Sally Sweeney, Family Planning New South Wales, Australia

005.6 Cervicovaginal metabolic profiling reveals the interplay between HPV, microbiota and inflammation in cervical carcinogenesis
- Melissa Herbst-Kralovetz, University of Arizona, USA

16:15 - 17:45

006. Oral Presentation Session 6
STI/HIV treatment efficacy and effectiveness
Chairpersons: Jonathan Ross, University of Birmingham, UK and Catriona Bradshaw, Melbourne Sexual Health Centre, Australia
Location: MR 11+12

006.1 Gentamicin for pharyngeal gonorrhea: A single-arm, non-blinded clinical trial
- Lindley Barbee, University of Washington, USA

006.2 In vitro combination testing and selection of resistance to ceftriaxone and azithromycin for N. gonorrhoeae
- Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Sweden

006.3 Efficacy of resistance guided therapy for Mycoplasma genitalium using doxycycline followed by azithromycin or moxifloxacin
- Duygu Durukan, Monash University, Australia

006.4 Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HPVac)
- Richard Gilson, University College London, UK

006.5 Do treatment rates suffer in a low-touch screening model? New York City sexual health clinics, 2017-2018
- Kelly Jamison, New York City Department of Health and Mental Hygiene, USA

006.6 Reduction in adherence to antiretroviral therapy during postpartum: Findings from a prospective cohort study
- Anthony Ajayi, University of Fort Hare, South Africa

16:15 - 17:45

007. Oral Presentation Session 7
Bugs, behaviour and beyond: New challenges for STI control among gay, bisexual and other men who have sex with men
Chairpersons: Nigel Field, University College London, UK and Chris Bourne, Centre For Population Health, Australia
Location: MR 8+15

007.1 Multiple lineages of multiresistant shigella in Australia
- Deborah Williamson, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Australia

007.2 Use of whole-genome sequencing to identify sexual transmission of shigella in men who have sex with men in England
- Holly Mitchell, University College London, UK

007.3 Sexually transmitted enteric infections in men who have sex with men: Preliminary findings from a cross-sectional study
- Holly Mitchell, University College London, UK

007.4 Incidence of sexual behaviors and relationship to the urethral microbiota among men who have sex with men (MSM) in Seattle
- Laura Chambers, University of Washington, USA

007.5 The index case's partnership status is important in predicting the likelihood of persistence of introduced XDR NG among MSM
- Ben Hui, University of New South Wales, Sydney, Australia

007.6 A RCT to facilitate psychosocial care among high risk MSM in Amsterdam, a SYNdemic BASed Intervention (Syn.bas.In Study)
- Roel Achterbergh, Public Health Service of Amsterdam, The Netherlands

16:15 - 19:00

PS01 Poster Viewing Session
Location: Exhibit Hall A

TUESDAY, JULY 16, 2019
07:00 - 08:00

CCS02 Clinical Case Series
Clinical cases from experts
Chairpersons: Julie Dombrowski, University of Washington, USA and Kees Rietmeijer, Rietmeijer Consulting, USA
Location: MR 8+15

08:15 - 08:50

CCS02.1 Dequalinium chloride vaginal tablets for recalcitrant *Trichomonas vaginalis* (TV): A case report
- Deborah Goode, Leeds Teaching Hospitals Trust, UK

CCS02.2 Penile intraepithelial neoplasia: Myriad presentations and intractable course
- Somesh Gupta, All India Institute of Medical Sciences, India

CCS02.3 Persisting urethritis in an immunocompromised patient
- William Geisler, University of Alabama at Birmingham, USA

08:50 - 10:00

PL07.1 Plenary 7
Global trends in HIV in the era of combination prevention – what progress have we made towards elimination?
Wafaa El-Sadr, Columbia University, USA

Panel:
- John P. Moore, Weill Cornell Medicine, USA
- Thomas Quinn, NIH, USA
- Emmanuel Ogua, PATH, USA
- Michael B. Mcmahon, University of Alabama, USA
- Marc Beyondin, UNAIDS, Geneva, Switzerland
- Shireen Mazhar, United Nations Development Programme, New York, USA
- Wafaa El-Sadr, Columbia University, USA
- Alex Kalinina, International Partnership for Microbicides, Maryland, USA
- David S. Vlahov, University of North Carolina at Chapel Hill, USA
- Erica Fischer, World Health Organization, Geneva, Switzerland

LOCATION: BALLROOM

PL07.2 Plenary 8
#MeToo movement, systems of power and sexual health and wellbeing: The widening of the #MeToo movement
Moderator: Jacky Jennings, Johns Hopkins School of Medicine, USA
Panel:
- Rebecca Thurston, University of Pittsburgh, USA
- Irin Carmon, New York Magazine & CNN Contributor, USA
Welcome by Elder, Coast Salish Nations
Chairperson: Ameeta Singh, University of Alberta, Canada

Coffee Break
Location: Exhibit Hall A

S08 Symposium 8
"Elders teach and youth reach": Indigenous conversations on sexual health
Chairpersons: Elder Roberta Price, Indigenous Co-Lead for the Family Medicine Residency Program, Canada and Larissa Wahpooseyay, Youthco, Canada
Location: MR 2+3

The idea for this symposium was developed through discussion with Elders from the Aboriginal Health Elders Advisory Council at Vancouver Coastal Health. This Council includes Elders from the Coast Salish peoples on whose land this conference is held, specifically the Sḵwx̱wú7mesh (Squamish), Selílíwitulh (Tsetel-Waututh), and xʷməθkʷəy̓əm (Musqueam) Nations, and from Nations from the Four Directions.

Support
Organization of this symposium is supported by members of the Conference níscaʔmát at Indigenous Sexual Health Committee. Financial support for this symposium is provided by the BC Centre for Disease Control, First Nations Health Authority, Indigenous Services Canada, and the Vancouver Foundation.

S09 Symposium 9
Prevention and care cascades
Chairpersons: Rebecca Guy, Kirby Institute, Australia and Nathan Lachowsky, University of Victoria / CBRC, Canada
Location: MR 11+12

S09.1 The relationship between demographics, health needs and the HIV care cascade outcomes: From infection to viral suppression
- Abigail Kroch, Skin/STD Clinic, Philippines

S09.2 Cascade of HIV prevention: A powerful tool to improve the implementation of DREAMS combination prevention in rural South Africa
- Maryam Shahmanesh, Institute for Global Health, University College London, UK

S09.3 Application of a cascade approach for guiding prevention of congenital syphilis
- Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru

S09.4 Cascades and other approaches to guide PrEP programming
- Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, South Africa

S10 Symposium 10
STIs in low and middle-income countries: Resurgent infections and evolving control measures
Chairpersons: Craig Cohen, UCSF, USA and Teodora Wi, World Health Organization, Switzerland
Location: MR 8+15

S10.1 High rates of curable STIs in low and middle income countries
- Connie Celum, University of Washington, USA

S10.2 Building STD clinical infrastructure in LMIC – role of general vs. specialized infrastructure
- Ligang Yang, Southern Medical University, China

S10.3 Cervical cancer prevention in LMICS: Are we on the path to elimination?
- Megan Huchko, Duke University, USA

S10.4 Self-care interventions for sexual and reproductive health and rights
- Manjula Narasimhan, World Health Organization, Switzerland

S11 Symposium 11
Research on the vaginal microbiome: Advances & controversies
Chairpersons: Jeannie Marrazzo, University of Alabama at Birmingham, USA and Sharon Hillier, University of Pittsburgh School of Medicine, USA
Location: MR 1

S11.1 Introduction to the vaginal microbiome preconference symposium
- Jeannie Marrazzo, University of Alabama at Birmingham School of Medicine, USA

S11.2 Lessons learned from the pre-meeting symposium on characterizing the vaginal microbiota through a blinded multi-laboratory collaboration
- Jen Balkus, University of Washington, USA

S11.3 The vaginal microenvironment prior to incident STI
- Rebecca Brotman, University of Maryland School of Medicine, USA

S11.4 Role of the genital tract microbiome in sexual and reproductive health: Report from the Keystone Symposium in Cape Town, 2018
- Janneke van de Wijgert, University of Liverpool, UK and University Medical Center Utrecht, The Netherlands

O08 Oral Presentation Session 8
Getting real with implementing PrEP 1: Gay, bisexual and other men who have sex with men
Chairpersons: Susan Blank, NYC Dept Of Health & Mental Hygiene, USA and Gilbert Yang, Skin/STD Clinic, Philippines
Location: Ballroom

O08.1 Pre-exposure prophylaxis in Brazil: Opportunities and challenges for men who have sex with men, Brazil, 2018
- Diego Calixto, Ministry of Health of Brazil, Brazil

O08.2 Sexual behaviour, risk and sexually transmitted infections before and after the introduction of the PrEP impact trial
- Louis MacGregor, University of Bristol, UK

O08.3 Rates of chlamydia and gonorrhoea testing and positivity before and after initiation of PrEP among MSM in US private settings
- Guoyu Tao, Centers for Disease Control and Prevention, USA

O08.4 Influence of HIV-status and PrEP use on high STI prevalences in MSM in Germany, 2018
- Klaus Jansen, Robert Koch Institute, Germany

O08.5 Trends in bacterial STI incidence and impact of PrEP use among MSM attending Western Sydney Sexual Health Centre (2013-2018)
- David Lewis, Western Sydney Local Health District, Australia

O08.6 Frequency and determinants of switching between daily or event-driven PrEP and discontinuing each regimen in Amsterdam MSM
- Liza Coyer, Public Health Service of Amsterdam, The Netherlands
10:45 - 12:15

**009 Oral Presentation Session 9**
Epidemiology and surveillance to inform practice and policy
Chairpersons: Viviane Bremer, Robert Koch-Institute, Germany and Hannelore Götz, Public Health Service Rotterdam-Rijnmond, The Netherlands
Location: MR 13

- 009.1 The Netherlands chlamydia cohort study: Pregnancies in women with and without a previous chlamydia infection - Bernice Hoenderboom, National Institute for Public Health and the Environment, The Netherlands
- 009.2 Declines in chlamydia-associated PID at SSHS in England since 2007: What might this tell us about chlamydia control? - Paddy Horner, University of Bristol, UK
- 009.3 Potential *Neisseria gonorrhoeae* outbreak in heterosexuals younger than 25 revealed three clusters by culture-free genotyping - Brian Van Der Veer, Maastricht University Medical Center (MUMC+), The Netherlands
- 009.4 HIV and HCV among clients of female sex workers in Dnipro, Ukraine - Marissa Becker, University of Manitoba, Canada
- 009.5 Hepatitis C incidence rate among people who inject drug (PWID) in British Columbia from 2000 to 2015 - YiQiao Li, British Columbia Center for Disease Control, Canada
- 009.6 Development of an integrated data mart for surveillance of sexually transmitted and bloodborne infections (STIBBI) - Jason Wong, BC Centre for Disease Control, Canada

12:15 - 13:45

**ASTDA Awards Luncheon**
Location: Ballroom C (West Building)

13:45 - 14:20

**PL09.1 Plenary 9**
Chairperson: William Geisler, University of Alabama at Birmingham, USA
Understanding chlamydia pathogenesis
Kevin Hybiske, University of Washington, USA

14:20 - 14:55

**PL10.1 Plenary 10**
Chairperson: Sinead Delany-Moretwe, Wits Reproductive Health and HIV Institute, South Africa
The global HIV response at 40
David Wilson, World Bank, USA

14:55 - 15:30

**PL11.1 Plenary 11**
Chairperson: King Holmes, University of Washington, USA
Global health legacies, sustainable development goals, and implications for sexual & reproductive health
David Peters, Johns Hopkins University, USA

15:30 - 16:15

Coffee Break
Location: Exhibit Hall A

16:15 - 17:45

**S12 Symposium 12**
New approaches for STI vaccines
Chairpersons: Anna Wald, University of Washington, USA and Sami Gottlieb, World Health Organization, Switzerland
Location: MR 2+3

- S12.1 Progress towards a gonorrhea vaccine - Kate Seib, Griffith University, Australia
- S12.2 A tri-antigen protective syphilis vaccine design that enhances treponemal clearance and inhibits pathogen dissemination - Lorenzo Giacani, University of Washington, USA
- S12.3 Therapeutic vaccination to treat HPV disease: Lessons learned from high grade intraepithelial lesions - Margaret Madeleine (STI & HIV 2019 World Congress Scholarship Recipient), Fred Hutchinson Cancer Research Center, USA
- S12.4 A mucosal *Chlamydia trachomatis* vaccine stimulates protective memory T cells - Michael Starnbach, Harvard University, USA

**S13 Symposium 13**
Controversies in clinical STI care
Chairpersons: Matthew Golden, University of Washington, USA and Christopher Fairley, Monash University, Australia
Location: MR 11+12

- S13.1 Does azithromycin have a future in the treatment of gonorrhoea and chlamydial infection? - Jane Hocking, University of Melbourne, Australia
- S13.2 Should enteric infections in MSM always be treated? - Mark Pakianathan, The London School of Hygiene & Tropical Medicine, UK
- S13.3 Do rectal bacterial STIs in women matter? Who should we test and when? - Christine Khoosopour, University of Washington, USA
- S13.4 HPV vaccination in MSM: Who should be vaccinated and is there a role for vaccination of older and/or HIV-positive MSM in preventing initial, persistent and recurrent HPV and related diseases? - David Templeton, University of Sydney, Australia

**S14 Symposium 14**
Sexual networks and STI transmission: From modelling to practice
Chairpersons: Katy Turner, University of Bristol, UK and Laith Abu-Raddad, Weill Cornell Medicine, Qatar
Location: Ballroom

- S14.1 Sexual contact networks, STI transmission and the effectiveness of interventions: Insights from mathematical modelling - Christian Althaus, University of Bern, Switzerland
- S14.2 Use of whole genome sequencing to explore transmission between sexual networks in an STI outbreak - Helen Fifer, Public Health England, UK
SCIENTIFIC PROGRAM (TUESDAY)

16:15 - 17:45

O10 Oral Presentation Session 10
Getting real with implementing PrEP 2
Chairpersons: Bradley Stoner, St. Louis STD/HIV Prevention Training Center, USA and Catherine O’Connor, Kirby Institute, Australia
Location: MR B+15

- O10.1 HIV pre-exposure prophylaxis (PrEP) indications and uptake vary by race, gender and insurance in a large clinic network
  - Maria Pyra, Howard Brown Health, USA

- O10.2 Impact of HIV-PrEP for female-sex-workers on community-wide awareness, uptake and perceptions in a rural-area Kwazulu-Natal
  - Natsayi Chimbindi, Africa Health Research Institute (AHRI), South Africa

- O10.3 High curable STI prevalence and incidence among young African women initiating PrEP in HPTN 082
  - Sinead Delany-Morettie, University of the Witwatersrand, South Africa

- O10.4 Scaling up HCV screening and treatment for eliminating HCV among MSM in UK in the era of HIV pre-exposure prophylaxis
  - Louis MacGregor, University of Bristol, UK

- O10.5 Patterns of HIV pre-exposure prophylaxis care one year after initiating PrEP, Baltimore City, Maryland 2015-2018
  - Linxuan Wu, Johns Hopkins University School of Medicine, USA

- O10.6 A longitudinal analysis of men who have sex with men’s condom use and attitudes during HIV antiretroviral prevention scale-up
  - Nathan Lachowsky, University of Victoria, Canada

16:15 - 17:45

O11 Oral Presentation Session 11
Improving the equity and effectiveness of sexual health care
Chairpersons: Elizabeth Foley, Solent NHS Trust, UK and Peter Saxton, University of Auckland, New Zealand
Location: MR 1

- O11.1 An update on the performance of STI services for gay and bisexual men across 40 cities: Preliminary results from EMIS-2017
  - Jason Doran, London School of Hygiene & Tropical Medicine, UK

- O11.2 How do the sexual networks of men who have sex with men in one mid-Atlantic city differ by race/ethnicity?
  - Jessica Wagner, Johns Hopkins University School of Medicine, USA

- O11.3 “You feel invisible”: A qualitative exploration of young LGBT+ people’s attitudes towards STI/HIV testing in primary care
  - Lorraine McDonagh, University College London, UK

- O11.4 Trans & gender diverse people’s experiences of sexual health care are associated with sexual health screening uptake
  - Denton Callander, New York University, USA

16:15 - 17:45

O12 Oral Presentation Session 12
Understanding relationships and partner strategies for STI control
Chairpersons: John Saunders, University College London, UK and Matthew Hogben, Centers for Disease Control and Prevention, USA
Location: MR 13

- O12.1 Exploring relationship duration among gay and bisexual men: A longitudinal event-level analysis
  - Kiffer Card, University of Victoria, Canada

- O12.2 Partnership context and consistent condom use among young African American men
  - Megan Clare Craig-Kuhn, Tulane University School of Public Health and Tropical Medicine, USA

- O12.3 Epidemiological impact of expedited partner therapy for men who have sex with men: A modeling study
  - Kevin Weiss, Emory University, USA

- O12.4 Effects of enhanced STI partner notification counselling in Cape Town: Randomized controlled trial
  - Catherine Mathews, South African Medical Research Council, South Africa

- O12.5 Partner notification outcomes for chlamydia/gonorrhea cases diagnosed through clinics vs GetCheckedOnline in British Columbia
  - Arina Zamanpour, British Columbia Centre for Disease Control, Canada

- O12.6 Contact tracing vs patient-delivered partner treatment for African American heterosexual men with chlamydia
  - Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

PS02 Poster Viewing Session
Location: Exhibit Hall A

Congress Dinner (Ticketed Event)
Location: Ballroom C + D (West Building)

WEDNESDAY, JULY 17, 2019

07:00 - 08:00

CCS03 Clinical Case Series - Cases from the clinic
Chairpersons: David Hawkins, Chelsea and Westminster Hospital, UK and Laura Bachmann, Centers for Disease Control and Prevention, USA
Location: MR B+15

- CCS03.1 Rapid PrEP reinitiation in a patient with ongoing risk
  - Negusse Ocbamichael PA-C, STD Clinic/Public Health-Seattle & King County at Harborview, USA

- CCS03.2 Neonatal HSV: Could this transmission have been prevented?
  - Elizabeth Foley, Solent NHS Trust, UK

- CCS03.3 Zoon balanitis in HIV-infected patient
  - Mauro Ramos, Ambulatório de Dermatologia Sanitária, Brazil
S15 Symposium 15
New approaches to STI diagnosis and prevention
Chairpersons: Laura Sycuro, University of Calgary, Canada and Ameeta Singh, University of Alberta, Canada
Location: Ballroom

S15.1 Four Treponema pallidum proteins detected in urine from syphilis-infected individuals using mass spectrometry
- Chris Kenyon, Institute of Tropical Medicine, Belgium

S15.2 CRISPR Diagnostics: Expanding the nucleic acid detection toolbox by harnessing microbial diversity
- Jonathan Gootenberg, Massachusetts Institute of Technology, USA

S15.3 Reducing the global burden of infectious diseases through precision infection management (PIM)
- Ian Lewis, University of Calgary, Canada

S15.4 Combating HIV with nanomaterials
- Kim Woodrow, University of Washington, USA

S18 Symposium 18
Regional responses to global HIV/STI trends (IUSTI Special Symposium)
Chairpersons: Charotte Gaydos, Johns Hopkins University, USA and Kaushal Verma, Indian Institute of Science, India
Location: MR 13

S18.1 An update on the status of HIV/STIs in IUSTI’s five regions
- Francis Ndowa, Skin & GU Medicine Clinic, Harare, Zimbabwe

S18.2 Bridging the gap - best practice global examples of integration of HIV and STI services
- Janet Wilson, National Health Service, UK

S18.3 Improving the sexual and reproductive health of women living with HIV
- Angelica Espinosa Miranda, Universidade Federal do Espirito Santo, Brazil

S18.4 Engaging culturally and linguistically diverse populations in HIV/STI services: Challenges and opportunities
- Shailendra Sawleshwarkar, University of Sydney, Australia
O13 Oral Presentation Session 13
Working towards sexual health equity: Understanding context
Chairpersons: Angelika Starý, Outpatients Centre for STI, Austria and Sunil Sethi, PGIMER, India
Location: MR 1

013.1 Factors associated with safer sex efficacy among Northern and indigenous youth in the Northwest Territories, Canada
- Carmen Logie, University of Toronto, Canada

013.2 Mixed methods analysis: Role of parents, peers and perceived severity of sexual health outcomes among Native American youth
- Lauren Tingley, Johns Hopkins University, USA

013.3 High prevalence of cervico-vaginal infections among female adolescents in four urban regions of Panama
- Amanda Gabster, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama

013.4 Patterns of drug use among MSM in Amsterdam and sexually transmitted infections, The Netherlands: A cluster analysis
- Roel Achterbergh, Public Health Service of Amsterdam, The Netherlands

013.5 Reaching home-based female sex workers with preventive sexual health care services in The Netherlands
- Charlotte Peters, South Limburg Public Health Services, The Netherlands

013.6 Precarious legal immigration status linked to client condom refusal among sex workers in Metro Vancouver (2010-2018)
- Bronwyn McBride, Centre for Gender and Sexual Health Equity, Canada

O14 Oral Presentation Session 14
Improving the access and impact of STI testing
Chairpersons: Angelika Starý, Outpatients Centre for STI, Austria and Sunil Sethi, PGIMER, India
Location: MR 8+15

014.1 Optimizing screening for chlamydia: Is there a role for screening heterosexual men?
- Minttu Rönn, Harvard T.H. Chan School of Public Health, USA

014.2 Can community Chlamydia trachomatis screening of young heterosexual men help identify infected networks?
- Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

014.3 Disparities in access to HIV point-of-care testing: The non-urban Canadian context
- Jacqueline Gahagan, Dalhousie University, Canada

014.4 Implementation of point of care gonorrhea and chlamydia testing in an STD clinic PrEP program, San Francisco, 2017-2018
- Stephanie Cohen, San Francisco Department of Public Health, USA

014.5 Chlamydia trachomatis testing: A national evaluation of internet based self-sampling in Sweden
- Björn Herrmann, Uppsala University Hospital, Sweden

014.6 mAfrican: Zenzele, a mobile-phone enabled HIV testing and linkage to care pathway for young people in rural South Africa
- Maryam Shahmanesh, University College London, UK

O15 Oral Presentation Session 15
Understanding perceptions and beliefs: Improving STI/HIV interventions and outcomes
Chairpersons: Lynn Barclay, American Sexual Health Association, USA and Charlotte Bell, Royal Adelaide Hospital, Australia
Location: MR 9

015.1 “A PrEP user is someone who has a lot of bareback”: A qualitative study of acceptability of PrEP in MSM in Lebanon
- Ismael Maatouk, Clemenceau Medical Center, Lebanon

015.2 Interested? Why or why not? STI clinic client perceptions of bacterial STI vaccines in British Columbia, Canada
- Kara Plotnikoff, University of British Columbia, Canada

015.3 Development of a scale measuring stigma towards alcohol abstinence among people living with HIV in Vietnam
- Kathryn Lancaster, The Ohio State University, USA

015.4 Predictors of incorrect HIV care initiation beliefs among people living with HIV/AIDS in Chókwè District, Mozambique
- Christine Hara, Public Health Institute, Mozambique

015.5 Syphilis risk perceptions among repeatedly infected men who have sex with men in Beirut, Lebanon
- Ismael Maatouk, Clemenceau Medical Center, Lebanon

015.5 Women’s approaches to involving others in making HIV trial enrollment decisions while pregnant in the US and Malawi
- Kristen Sullivan, University of North Carolina at Chapel Hill, USA

Break

S19 Symposium 19
Global public health approaches to gonorrhea prevention and the threat of antibiotic resistance
Chairpersons: Rupert Kaul, University of Toronto, Canada and Helen Fifer, Public Health England, UK
Location: MR 11+12

S19.1 Perspectives from North America
- Karen Schlanger, Center for Disease Control and Prevention, USA

S19.2 Perspectives from Brazil and Latin America
- Adele Schwartz Benzaken, Tropical Medicine Foundation, Manaus, Amazonas

S19.3 Perspectives from Thailand
- Pachara Sirivongrangson, Thailand Ministry of Public Health, Thailand

S19.4 Public health approaches to gonorrhea prevention and the threat of antibiotic resistance – perspectives from Europe
- Olilla Mårdh, European Centre for Disease Prevention and Control (ECDC), Sweden

S20 Symposium 20
Criminalization, the law and sexual health
Chairpersons: Helen Ward, Imperial College London, UK and Michel Alary, CHU de Québec - Université Laval, Canada
Location: Ballroom

S20.1 Understanding how laws and policies affect HIV prevention practices: A theoretical approach
- Morten Skovdal, University of Copenhagen, Denmark
S20.2 Intersectionality, criminalisation and sexual health  
- Carmen Logie, University of Toronto, Canada

S20.3 The health impacts of sex work criminalization: A review of the evidence  
- Lucy Platt, London School of Hygiene & Tropical Medicine, UK

S20.4 Criminalisation of HIV transmission in the era of U=U  
- Michael Brady, Kings College Hospital/Terrence Higgins Trust, UK

13:45 - 15:15  

S21 Symposium 21  
Building a human infrastructure for STI prevention: Beyond community engagement, consultation and advisory boards  
Chairpersons: Deborah Money, University of British Columbia, Canada and Gail Bolan, Centers for Disease Control and Prevention (CDC), USA  
Location: MR 2+3

S21.1 Youth and community based research  
- Sarah Flicker, York University, Canada

S21.2 Addressing anti-LGBT stigma and medical mistrust through a data-informed approach to community engagement  
- Errol Fields, Johns Hopkins University, USA

S21.3 Authentic and successful community engagement for STI/HIV prevention, screening and treatment in rural and urban settings  
- Scott Rhodes, University of North Carolina, USA

S21.4 Spurring innovation in improving community engagement for STI prevention  
- Weiming Tang, University of North Carolina Project-China, China

13:45 - 15:15  

O16 Oral Presentation Session 16  
Host-pathogen interactions  
Chairpersons: Juan Salazar, UCONN School of Medicine, USA and Lyle McKinnon, University of Manitoba, Canada  
Location: MR 9

O16.1 Therapeutic effect of indoleamine 2,3-dioxygenase (IDO) inhibitor in the male genital inflammation  
- Shin Ohira, Kawasaki Medical School, Japan

O16.2 Mapping regions of host attachment in the T. pallidum adhesin Tp0751; Function-informed vaccine design  
- Sean Waugh, University of Victoria, Canada

O16.3 Cytokine immune response against natural human papillomavirus infection among men in Kisumu, Kenya  
- Raphael Ondondo, Masinde Muliro University of Science and Technology, Kenya

O16.4 Structural similarity of Treponema pallidum protein Tp0225 with human toll-like receptor 2  
- Simon Houston, University of Victoria, Canada

O16.5 Targeting complement receptor 3 on primary human cervical cells has the potential to cure Neisseria gonorrhoeae infection  
- Jennifer Edwards, The Research Institute at Nationwide Children's Hospital and The Ohio State University, USA

O16.6 Basic science aids syphilis vaccine development: Bloodstream spreading by the syphilis spirochete Treponema pallidum  
- Karen Lithgow, University of Victoria, Canada

13:45 - 15:15  

O17 Oral Presentation Session 17  
Screening and vaccination  
Chairpersons: Basil Donovan, Kirby Institute, Australia and Marc Steben, INSPIQ, Canada  
Location: MR 1

O17.1 HPV FOCAL 48 month exit results by age for women HPV or LBC negative at baseline screening  
- Gina Ogilvie, University of British Columbia, Canada

O17.2 Women’s experiences with primary human papillomavirus (HPV) testing for cervix screening: HPV FOCAL exit survey results  
- Laurie Smith, BC Cancer, Canada

O17.3 Declining rates of cervical intraepithelial neoplasia after introduction of the HPV vaccine in British Columbia, Canada  
- Robine Donken, BC Children's Research Institute, Canada

O17.4 Impact of the human papillomavirus immunization program on rates of anogenital warts in British Columbia, Canada 2000-2017  
- Christine Lukac, University of British Columbia, Canada

O17.5 Declining trends in anogenital warts since HPV vaccine introduction in a large urban health system, 2013-2017  
- Linda Niccolai, Yale School of Public Health, USA

O17.6 Parents’/healthcare providers’ knowledge, attitude and perception of school-based HPV vaccination program in Lagos, Nigeria  
- Adebola Adejimi, College of Medicine, University of Lagos, Nigeria

O18 Oral Presentation Session 18  
Pills of white mercury: Syphilis prevalence, screening and prevention  
Chairpersons: Troy Grennan, BC Centre for Disease Control, Canada and Pingyu Zhou, Shanghai Skin Disease Hospital, China  
Location: MR 13

O18.1 Prevalence of active syphilis among transwomen in São Paulo, Brazil  
- Beatriz Paiatto, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil

O18.2 Estimating disease burden of maternal syphilis and associated adverse pregnancy outcomes in China  
- Yajie Wang, Dermatology Hospital of Southern Medical University, China

O18.3 Development of a syphilis serum repository for research and evaluation of syphilis diagnostics tests in the United States  
- Mayur Shukla, Centers for Disease Control and Prevention, USA

O18.4 Evaluation of routinized syphilis screening with HIV viral loads among men living with HIV  
- Ann Burchell, St. Michael's Hospital, Canada

O18.5 HIV seropositivity and early syphilis stage predictive of ocular syphilis diagnosis in British Columbia, Canada: 2010-2018  
- Hasan Hamze, University of British Columbia, Canada

O18.6 Prenatal care entry among pregnant women with syphilis who use methamphetamines: A key to congenital syphilis prevention  
- Rosalyn Plotzker, California Department of Public Health, USA
16:45 - 18:00

Monday, July 15, 2019
17:45 - 19:00 PS01 Poster Viewing Session
Location: Exhibit Hall A

P004 - The nationwide antimicrobial resistance surveillance system of sexually transmitted infections - South Korea, 2017-2018
Chang Hee Han, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Republic of Korea

P005 - Gonorrhea in the era of AMR, diagnostic needs for improved antimicrobial stewardship in low and middle income countries
Cecilia Ferreyra, FIND, Switzerland

P006 - “First test along then together” - the practice of couple’s HIV testing in Ethiopia
Tewodros Getachew Hailiemariam, The University of New South Wales, Australia

P007 - Uptake of couples HIV testing and counselling in Sub-Saharan Africa: A systematic review and meta-analysis
Tewodros Getachew Hailiemariam, The University of New South Wales, Australia

P008 - Diagnostic accuracy of Xpert MTB/RIF in detecting pulmonary tuberculosis among people living with HIV in western Nigeria
Saheed Usman, APIN Public Health Initiatives, Nigeria

P012 - A process evaluation of an incentivized home-based intervention to test and start (HTS) in rural KwaZulu-Natal, South Africa
Olufunfemi Adeagbo, Africa Health Research Institute, South Africa

P013 - Screening practices related to inconsistent Neisseria gonorrhoea and Chlamydia trachomatis nucleic acid amplification testing
Cherie Blair, University of California, Los Angeles, USA

P014 - Validating a clinical prediction rule for chlamydia and gonorrhea infection among online testers in British Columbia, Canada
Aidan Ablona, BC Centre for Disease Control, Canada

P015 - Introduction of chlamydia and gonorhea opt-out testing in a short-term correctional facility in Alberta, Canada
Patra Smyczek, Alberta Health Services, Canada

P017 - Effect of time change on adolescent and young people accessibility to AYFHC in Akure, Ondo state Nigeria
Onesmus Awanfo, Federal University of Technology Akure, Nigeria

P018 - Pay-it-forward gonorrhea and chlamydia testing among Chinese men who have sex with men: A cluster randomized controlled trial
Tianhe Zhang, University of North Carolina Project-China, China

P019 - Implementing home-sampling strategies to engage young heterosexuals in Chlamydia trachomatis re-testing and peer-testing
Nicole Dukers-Muijters, Public Health Service South Limburg, Netherlands

P020 - Urisponge™ facilitate urine collection and transportation for the detection of STD with the Amplesys™ TM II STI-7 assay
Santina Castriciano, Copan Italia Spa, Canada

P021 - Use of non-FDA cleared assays for detection of STIs in children being evaluated for suspected sexual abuse
Margaret Hammerschlag, State University of New York Downstate Medical Center, USA

P022 - Antenatal testing for curable STIs compared to syndromic management in Botswana: A cost-effectiveness study
Adriane Wynn, UCSD, USA

P023 - A mixed-methods analysis of a pay-it-forward gonorrhea/chlamydia testing program among men who have sex with men in China
Wenting Huang, University of North Carolina at Chapel Hill Project-China, China

P024 - Targeted point-of-care testing compared to syndromic management of urogenital infections in Rwandan women
Janneke Van De Wijgert, University Medical Center Utrecht, Netherlands

P025 - Automation and optimization strategies in a molecular lab to reduce an improved workflow for STI surveillance studies
Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany

P026 - Frequency of STD testing services among commercially insured patients with high risk sexual behaviors
Sagar Kumar, Centers for Disease Control and Prevention, USA

P027 - Safety and effectiveness of same-day screening and treatment among youth in Los Angeles, California
Elin Kezur, UCLA, USA

P029 - Multi-target PCs - the new multi-tool of STI diagnostics
Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany

P030 - Pilot implementation of a home-care program for chlamydia, gonorrhea and syphilis testing in HIV positive MSM
Nicole Dukers-Muijters, Public Health Service South Limburg, Netherlands

P031 - Using intervention mapping to develop a home-care program for men who have sex with men to get themselves tested for HIV/STI
Nicole Dukers-Muijters, Public Health Service South Limburg, Netherlands

P032 - Alone but supported with an innovative HIV self-testing app: Qualitative results from a large cohort study in South Africa
Ricky Janssen, Maastricht University, Netherlands

P033 - Differentiation of common genital ulcer disease pathogens using sequential or parallel molecular testing
Chris McCowin, Roche Diagnostics Corp, USA

P034 - HIV self-testing and potential linkage to care among men who have sex with men in China: A cross-sectional online survey
Cheng Wang, Social Entrepreneurship to Spur Health (SSEH) Team, China

P035 - Impact of mass media exposure in getting HIV testing among urban women in Nepal
Bisesh Bajracharya, Support to the Health Sector Programme, Nepal

P036 - Predictors of lost to follow-up in a “test and treat” programme among women with high-risk sexual behaviour in Kampala, Uganda
Onesimus Kamakoo, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Uganda

P038 - Comparison of Amplesys™ II STI-7e v1.1 to Allplex™ CT/NG/IM/G/T for the detection of STI from urine collected with UniSponge™
Santina Castriciano, Copan Italia Spa, Canada

P039 - A central reference laboratory for antimicrobial resistant Neisseria gonorrhoea in the US Department of Defense June Early, Infectious Disease Clinical Research Program, USA

P040 - Making sense of HIV self-testing: Social representation in young Nigerians narratives for promoting HIV self-testing
Chris McGowin, Roche Diagnostics Corp, USA

P041 - How is the value of point-of-care tests for STIs negotiable in the context of a nationalised health system?
Agata Pacho, St Georges, University of London, UK

P043 - Regional differences in STI testing barriers among online testers in British Columbia, Canada
Mark Gilbert, BC Centre for Disease Control, Canada

P044 - Regional differences in use of GetCheckedOnline and client characteristics across British Columbia, Canada
Aidan Ablona, BC Centre for Disease Control, Canada
and gonorrhoeae infection among men who have sex with men in Myanmar: Self-efficacy and HIV testing behavior

Minth Pham, Burnet Institute, Australia

PS28 - Rates of primary and secondary syphilis among men who have sex with men (MSM) with men

Jesse Knight, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Canada

PS29 - Early sexual debut and non-consensual sex among Chinese men who have sex with men: A multi-city cross-sectional study

Weiming Tang, UINC Project-China, China

PS30 - Addressing underserved men who have sex with men (MSM): Advancing the sexual health approach for MSM in Vancouver

Nathan Lachowsky, University of Victoria, Canada

PS31 - Conception mixing and the social geography of partner selection among sexual minority men in Toronto, Canada

Donne Geisert, University of Toronto, Canada

PS32 - The sexual behaviour and health of heterosexual-identifying men who have sex with men: A systematic review

Tyrone Curtis, University College London, UK

PS33 - Hepatitis A vaccine uptake among men who have sex with men from a targeted vaccination program in Melbourne in 2018

Lenka Vodstrcil, Monash University, Australia

PS35 - Conception & Amp, sexual: A quantitative study on sexualized drug use in men with sex in men and non-consensual sex

Martijn Van Rooijen, Public Health Service of Amsterdam, Netherlands

PS36 - High HIV incidence among men who have sex in eight Chinese cities: Results from a cohort study

Weiming Tang, UINC Project-China, China

PS39 - Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among MSM in Mozambique

Amina Hanifali, Institut National d’Hygiène, Morocco

PS40 - HPV (viro) prevalence among young MSM visiting the STI clinic: Opportunities for targeted HPV vaccination

Petr Wostenberg, and daily regionals

PS41 - To pool or not to pool STI samples in MSM using PrEP

Inth De Baetselier, Institute of Tropical Medicine, Belgium

PS42 - Prevalence of STIs among MSM initiating PrEP in West-Africa (CoHMSM-PrEP ANRS 12369 - Expertise France)

Inth De Baetselier, Institute of Tropical Medicine, Belgium

PS43 - Cost-effectiveness of pre-exposure prophylaxis in MSM with event-driven and daily regimens

Maarten Reitsma, RIVM, Netherlands

PS44 - Trends in recreational drug use and associations with CAS, HIV and STI among HIV-negative MSM in Amsterdam between 2006-2017

Liza Coyer, Public Health Service of Amsterdam, Netherlands

PS45 - Trends in HIV infection and AIDS in men who have sex with men (MSM): Adults compared to young people in Sao Paulo, Brazil

Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

PS46 - “STIs are everyone’s responsibility”: A new conceptual understanding of STI screening among gay and bisexual men

Dentaro Araya, Vancouver General Hospital, Canada

PS47 - Relationship length of gay male couples and sexually transmitted infections

Liping Vandenberghe, UNAIDS

PS48 - Acute gastroenteritis in men-who-have-sex-with-men in Toronto, Canada

Stefania Capece, Fred Hutchinson Cancer Research Center, USA

PS49 - What is the optimal testing strategy for oropharyngeal Neisseria gonorrhoeae in MSM visiting STI clinics? Christian Hoebe, Public Health Service South Limburg, Maasstricht University Medical Center (MUMC+), Netherlands

PS50 - High awareness but low uptake of HPV vaccine among young gay men in Ontario, Canada: Results from the C#Ruse project

Anna Yeung, St. Michael’s Hospital, Canada

PS51 - Extragenital gonorrhea positivity among men who have sex with men – STI Surveillance Network, 2015–2017

Winston Abara, CDC, USA

PS53 - Initiating a sexual network study among men who have sex with men: A mixed-methods pilot study

JaNelle Ricks, The Ohio State University, USA

PS54 - Adherence and sexually transmitted infections among MSM receiving care in a community-based HIV PrEP clinic in the deep South

Paul St. Clair, USA

PS55 - Monitoring HIV and syphilis co-infection among men who have sex with men in Brazil, 2009-2016

MARK Guimarães, Brazil

PS56 - History of STI therapy and willingness of prep among HIV-negative MSM cohort in Japan

Misaok Takanou, National Center for Global Health and Medicine, Japan

PS57 - “Flux NZ?”: An online national cohort investigating HIV, STI and drug-related practices among New Zealand gay and bisexual men

Peter Saxton, University of Auckland, New Zealand

PS58 - Sexual health, syndemics and assets among men who have sex with men. Secondary analysis of multi-national surveys

Paul Flowers, University of Glasgow, UK

PS59 - Incarceration, stress and sexual risk-taking: An intersectional analysis of black men who have sex in the deep south

Denton Callander, New York University, USA

PS60 - HIV preventative behaviour during last sex with a non-steady partner – self-reported data from 113,000 MSM from 66 countries

Ulrich Marcus, Robert Koch-Institut, Germany

PS61 - Developing surveillance tools to measure MSM’s HIV infection risk in the era of complex biobehavioural prevention strategies

Jamie Francis, Glasgow Caledonian University, UK

PS62 - Health seeking behaviour and acceptability of online outreach efforts among MSM using sex-seeking apps/web sites

David Greenman, University of Toronto, Canada

PS63 - MSM predictive modeling within a large, linked data-base of laboratory, surveillance, and administrative healthcare records

Travis Salway, BC Centre for Disease Control, Canada

PS64 - Outcomes of anal HPV screening in HIV+ men who have sex with men attending high resolution anoscopy clinic in Canada

Angel Chu, Alberta Health Services, Canada

PS65 - Personalized cognitive counseling (PCC) to reduce HIV infection following rectal gonorrhoea/chlamydia diagnosis among MSM in Peru

Juyer Floor, UCLA Geffen School of Medicine, USA

PS66 - The uptake of non-occupational HIV postexposure prophylaxis among MSM: A systematic review and meta-analysis

Jonathan Wang, School of Public Health, Sun Yat-sen University, China

PS67 - Factors influencing gay and queer men’s acceptability of integrating substance use care within sexual healthcare settings

Caroline Minzaks, BC Centre on Substance Use, Canada

PS52 - HIV testing uptake among young men who have sex with men in the USA: Effectiveness and HIV testing behavior

Minh Pham, Burnet Institute, Australia

PS53 - HIV testing uptake among young men who have sex with men in the USA: Self-efficacy and HIV testing behavior

Minh Pham, Burnet Institute, Australia

PS54 - What is the optimal testing strategy for oropharyngeal Neisseria gonorrhoeae in MSM visiting STI clinics? Christian Hoebe, Public Health Service South Limburg, Maasstricht University Medical Center (MUMC+), Netherlands

PS55 - High awareness but low uptake of HPV vaccine among young gay men in Ontario, Canada: Results from the C#Ruse project

Anna Yeung, St. Michael’s Hospital, Canada

PS56 - Extragenital gonorrhea positivity among men who have sex with men – STI Surveillance Network, 2015–2017

Winston Abara, CDC, USA

PS57 - Initiating a sexual network study among men who have sex with men: A mixed-methods pilot study

JaNelle Ricks, The Ohio State University, USA

PS58 - Adherence and sexually transmitted infections among MSM receiving care in a community-based HIV PrEP clinic in the deep South

Paul St. Clair, USA

PS59 - Monitoring HIV and syphilis co-infection among men who have sex with men in Brazil, 2009-2016

MARK Guimarães, Brazil

PS60 - History of STI therapy and willingness of prep among HIV-negative MSM cohort in Japan

Misaok Takanou, National Center for Global Health and Medicine, Japan

PS61 - Developing surveillance tools to measure MSM’s HIV infection risk in the era of complex biobehavioural prevention strategies

Jamie Francis, Glasgow Caledonian University, UK

PS62 - Health seeking behaviour and acceptability of online outreach efforts among MSM using sex-seeking apps/web sites

David Greenman, University of Toronto, Canada

PS63 - MSM predictive modeling within a large, linked data-base of laboratory, surveillance, and administrative healthcare records

Travis Salway, BC Centre for Disease Control, Canada

PS64 - Outcomes of anal HPV screening in HIV+ men who have sex with men attending high resolution anoscopy clinic in Canada

Angel Chu, Alberta Health Services, Canada

PS65 - Personalized cognitive counseling (PCC) to reduce HIV infection following rectal gonorrhoea/chlamydia diagnosis among MSM in Peru

Juyer Floor, UCLA Geffen School of Medicine, USA

PS66 - The uptake of non-occupational HIV postexposure prophylaxis among MSM: A systematic review and meta-analysis

Jonathan Wang, School of Public Health, Sun Yat-sen University, China

PS67 - Factors influencing gay and queer men’s acceptability of integrating substance use care within sexual healthcare settings

Caroline Minzaks, BC Centre on Substance Use, Canada
**P745 - The pregnancy syphilis cascade of care: “95-95-95” goals for reducing of congenital syphilis in the state of Sao Paulo, Brazil**

- Carmen Silva Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

**P746 - Maternal to child transmission prevention program for syphilis and HIV in Brazil: Missed opportunities**

- Angelica Miranda, Universidade Federal do Espirito Santo, Brazil

**P747 - Characteristics of chlamydia/gonorrhea infections associated with a subsequent syphilis diagnosis in British Columbia, Canada**

- Theodors Consolation, BC Centre for Disease Control, Canada

**P748 - Syphilis diagnostic test of STANDARD™ Q Syphilis Ab using fingerprick whole blood and screen on high risk populations**

- Rahma Lubis, Faculty of Medicine Universitas Indonesia/dr. Cipto Mangunkusumo National Hospital, Jakarta, Indonesia

**P750 - A comparison of Treponema pallidum molecular typing systems: MLST vs. EDCCT**

- Sharon Sali, University of Washington, USA

**P751 - Evaluation of a syphilis awareness campaign for gay, bisexual and other MSM (gbMSM): did we reach our targeted audience?**

- Jason Wong, BC Centre for Disease Control, Canada

**P752 - Under-sensitised non-trypomastigote tests: Implications for syphilis management**

- John Scotties, Community Initiative for AIDS Research, Canada

**P753 - Monitoring the evaluation of congenital syphilis cases in the state of Sao Paulo, 2007 to 2011**

- Carmen Silva Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

**P754 - Quantitation of cytokines in rabbits following tri-antigen vaccine cocktail immunization and 7 pallidum challenge**

- Charnnie Sodornes, University of Washington, USA

**P755 - Treponema pallidum stimulated macrophage-derived exosomal miR-146-5p decreased monocyte transendothelial migration**

- Giao-Quang Wang, Institute of Dermatology, Chinese Academy of Medical Sciences, China

**P756 - Risk factors for primary and secondary syphilis among females in Chicago, 2010-2017**

- Kimberly Stanford, University of Chicago, USA

**P757 - An evaluation of the provincial ‘Syphilis’ campaign in British Columbia, Canada**

- Vanessa Ryan, BC Centre For Disease Control, Canada

**P758 - Use of a rapid syphilis test for diagnosis among patients presenting to an STI clinic in North Carolina, USA**

- Arlene Seña, University of North Carolina at Chapel Hill, USA

**P759 - Evaluation of the bottom of it: Sexual positioning and syphilis stage at diagnosis among men who have sex with men**

- Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

**P760 - Added value of Treponema pallidum PCR in diagnosing early syphilis**

- Ing Van Loo, Maastricht University Medical Center, Netherlands

**P761 - Slings and arrows of syphilis surveillance: The department of defense experience with administrative case finding**

- Eric Larsen, USUHS, USA

**P762 - Sex, drugs and the internet – the perfect storm for syphilis in black gay and bisexual men (BMSM)**

- Jacky Jennings, Johns Hopkins University School of Medicine, USA

**P764 - The evolution of an infectious syphilis epidemic in a Canadian urban setting**

- Souradeep Shaw, University of Manitoba, Canada

**P765 - A systematic review on alternative treatments for maternal syphilis**

- Ashwarya Raich, UCLA David Geffen School of Medicine, USA

**P766 - Jarisch-Herxheimer reaction in central nervous system among neurosyphilis patients: discontinuation of therapy or not?**

- Ru-Rui Peng, Sexually Transmitted Disease Institute, Shanghai Skin Disease Hospital, China

**P767 - Clinical trial of Cefixime for the treatment of Early Syphilis - Preliminary results**

- Chrysantus Stafylos, UCLA David Geffen School of Medicine, USA

**P768 - Gastric syphilis: A case of gastric syphilis developed into neurosyphilis**

- Lin Zhu, Shanghai Skin Disease Hospital, China

**P769 - Increased detection rates of primary syphilis by PCR in a Province of Portugal**

- Pirenilla Naidu, Provincial Laboratory for Public Health, Canada

**P770 - Prevalence of bacterial sexually transmitted infections and co-infection with HIV among MSM and TW in Tijuana, Mexico**

- Claire Brissow, University of California San Diego, USA

**P771 - Hepatitis C is not a problem for female transgenders in Goa,central India**

- MÁrcia Souza, Universidade Federal de Goias, Brazil

**P772 - HIV epidemiology among men who have sex with men and transgender women in Myanmar: Data from community-based surveys**

- Vanessa Veronese, CPOP, Australia

**P773 - Difference between transmitted and transmitted for HIV prevalence and risk behaviors**

- Sheila Teles, Universidade Federal de Goais, Brazil

**P774 - HIV infection in transgender women from a region far from the epicenter of the HIV epidemic in Brazil – preliminary results**

- Sheila Teles, Universidade Federal de Goais, Brazil

**P775 - Pre-exposure prophylaxis use among trans and gender diverse people: Characteristics and behaviour from the EPIC-NSW trial**

- Benjamin Bavinton, University of New South Wales, Sydney, Australia

**P777 - Patterns of HIV and STI among transgender women in eastern and southern U.S.: Interm baseline findings from the LTE cohort**

- Tonia Poteat, University of North Carolina School of Medicine, USA

**P778 - Factors associated with syphilis testing in transgender women in central-west Brazil**

- Sheila Teles, Universidade Federal de Goais, Brazil

**P779 - Prevalence of STIs and HIV in transgender women and men: A systematic review**

- Olivia Van Gemen, University of Alabama at Birmingham, USA

**P780 - Syphilis Among MSM/TW in the Americas: A systematic review and meta-analysis**

- Jesse Clark, UCLA Geffen School of Medicine, USA

**P781 - Trichomonas vaginalis positivity rates by HIV status**

- Sandor Dobos, University of Porto, University of Portu guitar teaching Hospital, Nigeria

**P782 - Comparison of vaginal speculum and non-speculum specimens in the diagnosis of Trichomonas vaginalis**

- Marionne Trebble, BD Life Sciences, Canada

**P783 - Bacterial vaginosis markers detected by BD MAX™ Vaginal Panel in relation to absence and presence of Trichomonas vaginalis**

- Marie-Helene Tremblay, BD Life Sciences, Canada

**P784 - Assessment of urethritis etiology among HIV-infected men attending an STI clinic in Lilongwe, Malawi**

- Mitch Matoga, UNC Project Malawi, Malawi

**P785 - Risk factors for incident non-gonococcal urethritis (NGU) in men who have sex with women (MSW) attending an STI clinic**

- Emily Rowlinson, University of Washington, USA

**P786 - Prevalence and Evolution of Post-azithromycin Persistent Nongonococcal Urethritis (NGU) Symptoms in Men**

- Stephen Jordan, Indiana University School of Medicine, USA

**P787 - Prevalence of Nongonococcal Urethritis (NGU) Symptomatic in Men**

- Stephen Jordan, Indiana University School of Medicine, USA

**P788 - Assessing the Gram stain smear (GSS) polymorphic neutrophil leukocyte (PMN) cutoff for diagnosing non-gonococcal urethritis (NGU)**

- Gina Leipertz, University of Washington, USA

**P789 - Antibody response to Mycoplasma genitalium in longitudinally infected men with non-gonococcal urethritis**

- Gwendolyn Wood, University of Washington, USA

**P790 - Accelerated HIV case finding and bridging enrolment gap for key populations in western Nigeria: A break-even in the 90-90-90**

- Saheed Usman, APIN Public Health Intiatives, Nigeria

**P791 - Prevalence of curable sexually transmitted infections among refugees: Global systematic review and meta-analysis**

- Ghina Mumtaz, American University of Beirut, Lebanon

**P792 - Size of female injecting drug users in 10 Nigerian states and implications for HIV/Reproductive health among female injecting drug users in Nigeria**

- Ismael Maatouk, Clemenceau Medical Center, Lebanon

**P793** - HIV/STI service coverage among key population in Nigeria - lessons from size estimation study in Abia and Taraba states

- Mark Fernandez, University Of Washington, USA

**P794 - Multi-epitope ELISAs overcome cross-reactivity and sensitivity of Chlamydia trachomatis and C. pneumoniae seroology**

- Bernhard Kaltenboeck, Aalborg University, USA

**P795 - Privacy and technology for young black men who have sex with men in the Southern US related to sexual care and research**

- Christina Mumy, University of Alabama at Birmingham, USA

**P796 - Penile microbiome and urethral cytokines of Kenyan men who have sex with men and who have sex with women**

- Supriya Mehta, University of Illinois at Chicago, USA

**P797 - Female sex workers and their attitude towards oral pre-exposure prophylaxis**

- Tinase Madzviti, University of Zimbabwe, Zimbabwe

**P798** - Transgender women in Lebanon: A qualitative study to understand HIV/STIs risk factors

- Ismael Maatouk, Clemenceau Medical Center, Lebanon

**P799 - Negotiating safer sexual relations with husband and associated STI/HIV vulnerabilities among married women in India**

- Deepanjali Vishwakarma, International Institute for Population Sciences, India
All Industry-Supported Symposia will be held at the Vancouver Convention Centre, East Building from Monday, July 15 to Wednesday, July 17.

**Monday, July 15**

**BD**

### Maintaining Vaginal Health: Complexities in Diagnosis and Management

*Breakfast Symposium Supported by BD Diagnostic Systems*

- Diagnostics for Women with Discharge: Including Both Vaginal and Cervical Causes - Barbara Van Der Pol
- Clinical Management of Vaginal Syndromes - Jeanne Marrazzo

Open to all registered delegates
Breakfast will be served

---

**Roche**

### Mycoplasma genitalium and the Evolution of Clinical Practice: What Matters for the Clinician and Laboratory

*Lunch Symposium Supported by Roche*

- Understanding *Mycoplasma genitalium*: Epidemiology and Clinical Significance - William M. Geisler
- Clinical Performance of the Cobas TV/MG Assay for the Detection of *Mycoplasma genitalium* - Barbara Van Der Pol

Open to all registered delegates
Lunch will be served (first-come, first-served)

---

**Abbott**

### Achieving Precision Diagnostics for Sexually Transmitted Infections to Improve Public Health

*Evening Symposium Supported by Abbott Molecular*

- Insights to Improve Operational Efficiencies in Molecular Testing for STIs - Dr. Kevin Nelson
- Innovative Approaches in STI testing and Precision Diagnostics - Dr. Ajith Jospeh

Appetizers and beverages will be served (first-come, first-served)

---

**Tuesday, July 16**

**Cepheid**

### Point of Care Molecular Testing and Improved Patient Outcomes

*Breakfast Symposium Supported by Cepheid*

- Extragenital Testing for Chlamydial and Gonorrheal Disease: Study Review - Claire C. Bristow
- Improved Patient Care with STI Screening - Pierre-Cédric B. Crouch

Open to all registered delegates
Breakfast will be served (first-come, first-served)

---

**Wednesday, July 17**

**Hologic**

### Aptima *Mycoplasma genitalium* Evaluation Study

*Breakfast Symposium Supported by Hologic*

- *Mycoplasma genitalium*: History of the Discovery, Detection and Treatment of a Sexually Transmitted Pathogen - Charlotte A. Gaydos
- *Mycoplasma genitalium* Testing in the US: Results from a Prospective, Multi-Center Clinical study - Damon Getman

Open to all registered delegates
Breakfast will be served (first-come, first-served)

---

**Hologic**

### Aptima Vaginosis and Vaginitis Evaluation Study

*Lunch Symposium Supported by Hologic*

- Vaginitis and Vaginosis: Challenges in Diagnosis and Treatment – Jane R. Schwebke
- Clinical Performance of the Aptima BV and Aptima CV/TV Assays for Vaginosis and Vaginitis – Craig Clark

Open to all registered delegates
Lunch will be served (first-come, first-served)

---

**Cepheid**

We are a better way.

Life is full of questions. Consolidated molecular diagnostic testing on Cepheid’s GeneXpert® System delivers better answers. We are advancing healthcare with accurate, fast results whenever and wherever they are needed.

www.Cepheidinternational.com

Please join us for a Cepheid Breakfast Symposium Point of Care Molecular Testing and Improved Patient Outcomes

**STI & HIV 2019 World Congress**

14-17 July 2019

Vancouver, Canada

Come visit us at the Cepheid at Booth #203

IVD. In Vitro Diagnostic Medical Device

This presentation was approved by the Scientific Program Committee as an independent activity held in conjunction with the STI & HIV 2019 World Congress, Joint Meeting of the 23rd ISSTDR & 20th IUSTI. This presentation is not sponsored or endorsed by STI & HIV 2019.
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Supported by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, July 13</td>
<td>08:00 – 12:30</td>
<td>ISSTDR Board Meeting <em>(By Invitation Only)</em></td>
<td>MR 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:30 – 13:00</td>
<td>ISSTDR Board Member-IUSTI Executive Committee Lunch <em>(By Invitation Only)</em></td>
<td>Meeting Level South Foyer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:00 – 18:00</td>
<td>IUSTI Executive Committee Meeting <em>(By Invitation Only)</em></td>
<td>MR 1</td>
<td></td>
</tr>
<tr>
<td>Sunday, July 14</td>
<td>12:00 – 13:00</td>
<td>UCLA &amp; WHO Lunch <em>(By Invitation Only)</em></td>
<td>MR 20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16:00 – 17:00</td>
<td>STD Journal Assoc. Editors Meeting <em>(By Invitation Only)</em></td>
<td>MR 20</td>
<td></td>
</tr>
<tr>
<td>Monday, July 15</td>
<td>07:00 - 08:00</td>
<td>ASTDA Young Investigator Mentor/Mentee Breakfast Session: Meet the Editor! <em>(By Invitation Only)</em></td>
<td>MR 11+12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:30 – 13:30</td>
<td>STI &amp; HIV World Congress 2021 - ISC/LSC Meeting <em>(By Invitation Only)</em></td>
<td>MR 13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:30 - 14:00</td>
<td>NIH Meeting <em>(By Invitation Only)</em></td>
<td>MR 9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:45 – 13:45</td>
<td>IUSTI General Assembly <em>(Members Only)</em></td>
<td>MR 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18:15 – 19:15</td>
<td>IUSTI-Canada AGM <em>(Members Only)</em></td>
<td>MR 1</td>
<td></td>
</tr>
<tr>
<td>Tuesday, July 16</td>
<td>07:00 – 08:00</td>
<td>Sexually Transmitted Infections Editorial Meeting <em>(By Invitation Only)</em></td>
<td>MR 13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>07:00 – 08:00</td>
<td>ASTDA Young Investigator Mentor/Mentee Breakfast Session: Meet the NIH! <em>(By Invitation Only)</em></td>
<td>MR 11+12</td>
<td></td>
</tr>
<tr>
<td>Wednesday, July 13</td>
<td>07:00 - 08:00</td>
<td>ASTDA Young Investigator Mentor/Mentee Breakfast Session: Sexual Harassment in Sexual Health Professions: Breaking Silence and Making Solutions <em>(By Invitation Only)</em></td>
<td>MR 11+12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:15 - 10:45</td>
<td>Canadian Institutes of Health Research HIV/AIDS and STBBI Strategic Plan Consultation Session <em>(By Invitation Only)</em></td>
<td>MR 19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:15 - 15:45</td>
<td>12:30 – 13:30</td>
<td>Mycoplasma genitalium Global Surveillance Meeting <em>(By Invitation Only)</em></td>
<td>MR 9</td>
</tr>
<tr>
<td></td>
<td>12:30 – 13:30</td>
<td>18:00 – 20:00</td>
<td>2nd IUSTI Executive Meeting <em>(By Invitation Only)</em></td>
<td>MR 1</td>
</tr>
<tr>
<td></td>
<td>18:00 – 20:30</td>
<td>18:00 – 20:30</td>
<td>4th Annual Public Health Applications of C. trachomatis Serology (PHACTS) Meeting</td>
<td>MR 13</td>
</tr>
</tbody>
</table>
**NETWORKING EVENTS**

**Saturday, July 13**
19:30 – 22:00  Presidents’ Dinner *(By Invitation Only)*  
*Location: The Teahouse, Stanley Park*

**Sunday, July 14**
19:30 – 21:00 Welcome Reception  
*Location: Exhibit Hall A*

**Monday, July 15**
17:45 – 19:00 Poster Viewing  
*Location: Exhibit Hall A*

19:30 – 22:00 Speakers’ Dinner *(By Invitation Only)*  
*Location: The Vancouver Club*

**Tuesday, July 16**
17:45 – 19:00 Poster Viewing  
*Location: Exhibit Hall A*

19:30 – 22:00 Congress Dinner *(Ticketed Event)*  
*Location: Ballroom C + D (West Building)*

**GENERAL INFORMATION**

**ABSTRACTS**
Abstracts selected for the STI & HIV 2019 World Congress are presented in Oral and Poster Sessions. All abstracts approved for presentation will be published online in the journal of Sexually Transmitted Infections on July 14, 2019.

**ATTIRE**
Business casual is appropriate. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

**BADGES**
Your personalized badge is your admission card to the Congress. For organizational and security reasons, badges must be worn at the congress venue at all times.

**CELL PHONES**
As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

**CERTIFICATE OF ATTENDANCE**
Congress attendees can request a ‘Certificate of Attendance’ by completing the Congress Evaluation Form available on the Congress website on the last day of the Congress. After completing the evaluation form you will be able to download your Certificate of Attendance.

**CME ACCREDITATION AND CME CERTIFICATE**
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of VCU Health Continuing Medical Education and International Conference Services, Ltd. VCU Health Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

VCU Health Continuing Medical Education designates this live activity for a maximum of 23 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Congress attendees can request a ‘CME Certificate’ by completing the Congress Evaluation Form available on the Congress website on the last day of the Congress. After completing the evaluation form you will be able to download your CME Certificate.

**EMERGENCY SERVICES AND FIRST AID EMERGENCY NUMBER**
In the event of a health, safety, or criminal emergency, dial 7500 from any of the house phones or +1 604 647 7500 from your mobile phone. The First Aid Office is located in the East Lobby next to the washrooms. Kindly note that the First Aid office is not staffed. For access please call the above-mentioned emergency numbers.

**EVALUATION SURVEY**
A Congress Evaluation Survey will be e-mailed to all delegates after the Congress. Please help us to improve the Congress by completing your Survey.

**EXHIBITION**
The exhibits are an integral part of the experience at the STI & HIV 2019 World Congress and will feature the latest in technology and research. The exhibits are located in East Exhibit Hall A, Street/Convention Level at the Vancouver Convention Centre, East Building.
GENERAL INFORMATION

EXHIBITION SHOW HOURS
Sunday, July 14 .......... 19:30 – 21:00 (Welcome Reception)
Monday, July 15 .......... 10:15 – 19:00
Tuesday, July 16 ........ 10:15 – 19:00
Wednesday, July 17 .... 10:15 – 15:45

JOIN THE CONVERSATION – STI & HIV 2019 WORLD CONGRESS OFFICIAL SOCIAL MEDIA ACCOUNTS
Share your experience and images from the STI & HIV 2019 World Congress with colleagues and friends via Facebook and Twitter. Follow our official social media feeds throughout the Congress: @ISSTDRIUSTI2019. We encourage you to tag your posts with #ISSTDR2019 and #IUSTIWorld2019.

www.facebook.com/ISSTDRIUSTI2019
www.twitter.com/ISSTDRIUSTI2019

LOST AND FOUND
Lost and Found items should be returned/claimed at the Registration Desk.

LUNCHES
There are many food options available in and around the convention centre. The Coal Harbour Café is located on the street level next to the registration area in the East Building. There is a food court located at the Waterfront Centre across the street from the Vancouver Convention Centre, with a variety of options to suit all tastes.

NETWORKING BREAKS
Breaks will take place in the following locations and at the following times. Refreshments will be provided.

Monday, July 15
10:15 – 10:45
15:30 - 16:15
Exhibit Hall A, Street/Convention Level

Tuesday, July 16
10:15 – 10:45
15:30 - 16:15
Exhibit Hall A, Street/Convention Level

Wednesday, July 17
10:15 – 10:45
15:15 - 15:45
Exhibit Hall A, Street/Convention Level

MOBILE APP
Supported by: Abbott

Download the free STI & HIV 2019 World Congress mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan, exhibitor bio, and general Conference and venue information on our easy to use app! The app is compatible with all iOS devices (iPhone, iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts. You must enable notifications on your device to receive these alerts.

Search “STI HIV” in the App Store (for Apple) or Google Play Store (for Android).

PARKING
Parking is available in the Vancouver Convention Centre West and East Building.

Vancouver Convention Centre East
999 Canada Place

WestPark
• Enter at the foot of Howe Street, obtain ticket from dispenser and proceed to P1 or P2.
• Use Convention Centre/Hotel elevators (not World Trade Centre elevators).
• For Convention Level: press “G” for Registration, Ballrooms and Exhibits.
• For Meeting Rooms: press “M”.

POSTER VIEWING
East Exhibit Hall A, Street/Convention Level

All posters have been split into two groups: Monday and Tuesday. A different set of posters will be displayed on these days so be sure to visit the Exhibit & Poster Hall. Posters will be on display for the entire day, but presenters will be standing by their poster during the poster viewing sessions.

OFFICIAL POSTER VIEWING SESSIONS
Monday, July 15 ........ 17:45 – 19:00
Tuesday, July 16 ........ 17:45 – 19:00

POSTER VIEWING IN THE EXHIBIT HALL DURING COFFEE BREAKS
10:15 – 10:45
15:30 – 16:15

PUBLIC TRANSPORTATION
Vancouver is a walkable city and all Congress hotels are within a maximum of 20-minute walking distance.

REGISTRATION COUNTER HOURS
Located in the lobby of the Vancouver Convention Centre East Building, Street/Convention Level.

Saturday, July 13............. 15:00 – 19:00
Sunday, July 14............. 07:30 – 20:00
Monday, July 15............ 06:30 – 16:00
Tuesday, July 16............ 06:30 – 16:00
Wednesday, July 17........ 06:30 – 15:00

SMOKING
It is against the law to smoke in any indoor public place or worksite, including pubs, bars, restaurants, and shopping centres. Designated smoking rooms are non-existent, and public transit, transit shelters, taxis and work vehicles are also smoke-free.

In addition, there is a 3-metre non-smoking “buffer zone” around public and work place doorways, opening windows and air intakes including apartments and condominiums.
**GENERAL INFORMATION**

**SPEAKER READY ROOM**

MR 10 in the East Building (on Meeting Room Level) is the designated Speaker Ready Room. Only digital material will be allowed for oral presentation (PowerPoint files).
- All oral presenters are requested to check-in at the Speaker Ready Room a minimum of 24 hours prior to your scheduled presentation, to review and upload your PowerPoint presentation.
- Once you have uploaded your PowerPoint, you may still make changes to it up to 4 hours before your presentation.
- If for any reason you are unable to meet this schedule, please inform the STI & HIV 2019 World Congress Secretariat at STIHIV2019-Speakers@icsevents.com before the Congress.
- PowerPoint presentations cannot be uploaded in the session rooms.
- Computers will be available for you in the Speaker Ready Room for your final check.
- Once the presentation has been checked, the technical staff will be responsible for its delivery to the session rooms in preparation for your presentation.

**Hours of Operation:**
- Saturday, July 13: 15:00 – 19:00
- Sunday, July 14: 07:00 – 18:30
- Monday, July 15: 06:30 – 16:30
- Tuesday, July 16: 06:30 – 16:30
- Wednesday, July 17: 06:30 – 16:00

**STAFF AND VOLUNTEERS**

Supported by: **Abbott**

Volunteers are working throughout the Convention Centre and are happy to assist with any questions delegates may have regarding the Congress or the Convention Centre. Delegates can easily locate volunteers by their volunteer shirts.

**WIRELESS INTERNET**

The Congress is happy to provide delegates with complimentary Wi-Fi.

Network: STI & HIV 2019 World Congress
Password: STIHIV2019

**DISCLAIMER**

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
Insight to work smarter, not harder
simpllicity / flexibility / efficiency

When you know where you’re going, you get there faster.
Transform your lab with the simplicity, flexibility and efficiency of the Molecular Work Area from Roche… proven performance with a clear path for sustainable sexual health testing now and for the future.

Come and learn more about Molecular Work Area and the broad menu it delivers at Booth 206

COBAS is a trademark of Roche.
©2019 Roche
Roche Molecular Diagnostics, Pleasanton, CA 94588 USA molecularworkarea.com MC--01379
Abbott Molecular | Booth #404
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries. (abbott.com)

BD Diagnostic Systems | Booth #105
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. (bd.com)

bioLytical Laboratories Inc. | Booth #104
bioLytical Laboratories based in Richmond, BC, is a privately-owned Canadian company focused on the research, development, and commercialization of rapid, point-of-care in-vitro medical diagnostics using its proprietary INSTI® technology platform. The INSTI product line provides highly accurate test results in 60 seconds or less with over 99% accuracy. (insti.com)

Center for Disease Detection | Booth #408
Center for Disease Detection (CDD) is one of the nation’s leading laboratories, providing testing to customers in all 50 states as well as internationally. Founded in 1990, CDD services federal, state and local government agencies, STD clinics, and organizations dedicated to sexual health. (cddmedical.com)

Cepheid | Booth #203
Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer. (cepheid.com)

Chembio Diagnostic Systems, Inc. | Booth #505
Chembio Diagnostic Systems, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. The novel DPP® technology offers broad market applications beyond infectious disease. (chembio.com)

Clinical Prevention Services – BC Centre For Disease Control | Booth #409
Clinical Prevention Services at the BC Centre for Disease Control (BCCDC) provides low-barrier, culturally safe services for diverse communities around the prevention, testing, diagnosis and treatment of STIs and HIV. STI and HIV services offered at the BCCDC include integrated care, provincial STI clinics, community sexual health services, and prevention interventions. (bccdc.ca)

Copan | Booth #401
With a rightful reputation for innovation, COPAN is the world leading manufacturer of collection and transport systems. In like manner, COPAN’s collaborative approach to pre-analytics has resulted in the development of FLOOSSwabs®, ESwab®, UTM® and modular laboratory automation, WASP® and WASPLab®. (copangroup.com)

EUROIMMUN AG a PerkinElmer Company | Booth #403
EUROIMMUN is an international provider of medical laboratory products with a growing molecular genetic diagnostics portfolio. The company’s EUROArray platform provides multiplex detection of sexually transmitted pathogens, HPV or dermatophytes. Real-time PCR tests for Zika virus and HSV-1/2 and microarrays for genetic risk determination in many different diseases complete the portfolio. (euroimmun.com)

GIANTmicrobes | Booth #412
GIANTmicrobes are educational products based on health and biology. Our adorable Herpes, Syphilis, HIV, Chlamydia, Gonorrhea, HPV and other STDs are used globally by public health agencies, medical organizations, healthcare professionals and educators as an engaging and memorable way to get people talking about infectious diseases and important health topics. (giantmicrobes.com)

Hologic | Booth #300
A global champion of women’s health, Hologic is an innovative medical technology company that enables healthier lives everywhere, every day through The Science of Sure: Clinical superiority that delivers life-changing diagnostic, detection, surgical and medical aesthetic products rooted in science and driven by technology. (hologic.com)
ImmunoPrecise Antibodies | Booth #504
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody solutions; delivering the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. Our comprehensive collection of discovery platforms include transgenic animals, B-cell selection, phage display, and hybridoma development. Our extensive experience with multiple transgenic platforms provides clients access to reliable and effective therapeutic human antibody selection, available through all ImmunoPrecise's discovery platforms. (immunoprecise.com)

IUSTI-Europe | Booth #100
The 33rd IUSTI-Europe Congress on Sexually Transmitted Infections will be held September 05 – 07, 2019 in Tallinn, Estonia. The meeting will take place in the historic venue of the Estonian National Opera in the heart of the medieval city. IUSTI-Europe 2019 Congress has been granted 11 European CME credits (ECMEC®s). (iusti2019.eu)

Mayer Labs | Booth #507
Featuring Kimono Condoms, Aqua Lube, and Today Contraceptive Sponge, institutional and retail accounts rely on Mayer Labs to produce the finest reproductive healthcare. ISO 13485 and MDSAP certified, and US FDA and Health Canada registered, Mayer Labs’ global sourcing, draws upon the finest manufacturing partnerships in Japan, India, Thailand, Korea, New York, and California to deliver the best in quality and user satisfaction. (mayerlabs.com)

Novosanis | Booth #406
Novosanis is a subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices. Our flagship device platform, Colli-Pee, is suited for volumetric and standardized collection of first-void urine improving the quality of diagnostics tests for infectious diseases and oncology. (novosanis.com)

Pauktuutit Inuit Women Of Canada | Booth #508
Pauktuutit is the national representative organization of Inuit women in Canada. We foster greater awareness of the needs of Inuit women, advocate for equality and social improvements, and encourage Inuit women's participation in the community, regional and national life of Canada. (https://www.pauktuutit.ca/)

Roche | Booth #206
As the world leader in in-vitro diagnostics, Roche offers a broad portfolio of instruments and assays for the screening, diagnosis and prevention of infectious diseases. With an ongoing focus on patient needs and the depth and breadth of our comprehensive portfolio, Roche is your partner for improving patient outcome by offering a wide range of solutions to Microbiologists, Clinical Researchers and Infection Preventionists. Visit our booth for the latest molecular, PCR-based assays and proven immunochemistry innovations. (diagnostics.roche.com)

SD Biosensor | Booth #204
SD Biosensor is an IVD manufacturer based in Korea. It offers a large range of portfolio such as rapid diagnostic, glucometer, ELISA test, immunochromatography and fluorescence analyzer etc. Currently SD Biosensor is developing new POC MDx platform which makes SD Biosensor a total diagnostic provider from screening to confirmatory test. (sdbiosensor.com)

Seegene Inc. | Booth #400
Seegene is the world’s leading developer of multiplex molecular technologies and diagnostic products. Seegene's innovative proprietary technologies enable the simultaneous detection, differentiation and quantification of multiple targets with high sensitivity, specificity and reproducibility and perform on unique streamlining automation solution. Seegene's products, in particular for sexually transmitted infections, provide accurate and comprehensive information on infected STI, BV and HPV pathogens. (seegene.com)

Shield Diagnostics | Booth #410
Shield Diagnostics’ mission is to provide clinicians with the ability to apply precision medicine to the most pressing bacterial infections. Our first rapid molecular test, Target-NG, evaluates Gonorrhea infections for antibiotic susceptibility to ciprofloxacin, as a rapid reflex to Gonorrhea & Chlamydia testing in our CLIA laboratory in San Jose, CA. (shielddx.com)

SpeeDx | Booth #200
SpeeDx specializes in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. SpeeDx has a portfolio of CE-IVD multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers. Resistance-guided therapy improves patient outcomes by empowering practitioners to make informed clinical decisions. (plexpcr.com)
Spot On Sciences | Booth # 201
Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research. HemaSpot™ devices enable collection of blood samples offering solutions for multiple markets including clinical research, biobanking, military field medicine and population studies. The company was founded to ultimately improve access to medical testing for home-bound, rural and economically disadvantaged patients by allowing easy sample collection and shipment. (spotonsciences.com)

STEMCELL Technologies | Booth #202
STEMCELL Technologies provides cell isolation products for studying HIV and other infectious diseases. Our cell separation technologies, EasySep™, RosetteSep™ and SepMate™ facilitate rapid human blood processing. SepMate™ registered as an IVD device, isolates PBMC in just 15 minutes. RoboSep™ fully automates EasySep™ cell isolation, minimizing sample handling and eliminating cross-contamination. (stemcell.com)

Stichting World STI & HIV Congress 2021 | Booth #407
Herewith we would like to welcome you to the 24th STI & HIV World Congress 2021, to be held from 18 until 21 July 2021 in Amsterdam, The Netherlands. The organisers have chosen "Sexual diversity and the city" as the conference theme, and they aim to address diversity, health and sexuality in the urban context. Amsterdam is a very popular destination and very easy to travel to. #sexualdiversityandthecity (stihiv2021.org)

World Health Organization | Booth #411
WHO has a vision for the attainment of the highest possible standard of sexual and reproductive health for all people. It strives for a world where all people’s rights to enjoy sexual and reproductive health and gender equality are protected and promoted, and all people, including adolescents and other underserved and marginalized populations, have access to comprehensive sexual and reproductive health information and services. (who.int/reproductivehealth)

Youth against AIDS | Booth #509
In a world impacted by major technological and social disruptions "Youth against AIDS" goes new ways to face the HIV & STI epidemic among young generations. "Youth against AIDS" is convinced that great innovations are necessary to meet the needs of the young target group, and to become a close partner in young peoples lives. "Youth against AIDS" builds networks to create innovation in prevention and to create a major change in young peoples individual health management. (youth-against-aids.org)
IF YOU THINK IT’S CHLAMYDIA.

AND IT ACTS LIKE CHLAMYDIA.

IT MIGHT BE MYCOPLASMA GENITALIUM.

Many healthcare providers are unfamiliar with *Mycoplasma genitalium*—that’s why awareness is so important.

Visit [HologicEd.com](http://HologicEd.com) for diagnosis and treatment strategies.

References:

ADS-02534-001 Rev. 002 © 2019 Hologic, Inc. All rights reserved. Hologic, Aptima and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.